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INTRODUCTION 
The immune system serves as a protective system against infectious agents such as 
bacteria, viruses and parasites. Foreign molecules (antigens) can be recognized by 
the immune system and induce an immune response resulting in destruction and 
elimination of the pathogens. In addition to infectious agents, also tumor cells can 
distingnish themselves from normal cells either by quantitative and/or qualitative 
different expression of genetic information. This idea forms the basis of cancer 
immunotherapy, which aims at the elimination of tumor cells using the patient's 
natural immune system. The concept of tumor-specific immune reactivity goes back 
to the postulation of immunesurveillance as formulated by Ehrlich in 1909 and 
adapted by Burnet in 1970. They proposed that the immune system might be 
capable of eliminating tumor cells in the same way that protects us from foreign 
agents, i.e. immunosurveillance. Although there might be immunesurveillance, this 
mechanism is not dominant, as tumor cells may escape the immune system resulting 
in uncontrolled cell proliferation and tumor formation. Therefore, effective anti-
cancer immunotherapy should be directed at the manipulation and enhancement of 
the immune capacity to fight cancer cells. This can be accomplished either in an 
active way, by activating and amplifying the destructive potential of the individual's 
endogenous immune cells able to recognize and destroy the tumor, or in a passive 
way by providing ex vivo activated immune cells with anti-tumor capacity to a 
tumor-bearing individual. 
The first known immunologically based treatment of cancer patients was performed at 
the end of the 19th century by Coley, who tried to induce an immune reaction against 
the tumor with bacterial extracts. This treatment resulted in tumor regression but with 
inconsistent results. Year's later, bacterial vaccines such as Bacillus Calmette-Guerin 
(BCG) or Corynebcu:terium parvum (C. parvum) were again used as immuno-
modulating agents to stimulate cellular and humoral immune reactivity. Other than in 
melanoma and bladder cancer, treatment with bacterial products was not very 
successful (1). This non-specific approach was followed by the use of cytokines to 
enhance the immune system. The use of cytokines in cancer treatment has been 
promising in experimental animal models but clioical results were disappointing mostly 
due to toxicity (2-4). 
When developments in the field of immunology and molecular biology allowed the 
production oflarge amounts of biological molecules (cytokines, monoclonal an1lbodies 
(mAb)) necessary to culture immune cells in vitro, the isolation, cloning, expansion and 
adoptive transfer of immune effector cells became possible (5-8). Together with the 
understanding of the nature of antigen recognition and the identification of tumor 
antigens it became possible to develop specific anti-tumor therapies. 
This introduction addresses basis principles of tumor immunology with focus on the 
current developments in immunotherapeutical approaches for cancer treatment. 
11 
chapter 1 
Effector mechanisms of the immune system 
The immune system can be divided into an innate and adaptive arm that together 
provides an effective defense system. Mechanisms of non-antigen specific innate 
immunity serve as the first line of defense. The innate immune system reacts directly 
to a pathogen by the activation of complement and the destruction of pathogens by 
neurophils and macrophages. An important role for the innate immune system is to 
recruit more phagocytic cells and effector molecules on the site of infection by the 
release of cytokines. When pathogens escape the innate immune system an adaptive 
immune response will follow with the formation of antigen-specific effector cells 
and immunological memory. Cells of the adaptive immune system bear specific 
receptors for recognition of antigens. The adaptive immune system can be further 
subdivided into the humoral immune response involving B lymphocytes that 
produces soluble antibodies (Ab) and the cellular immune response comprising 
cytotoxic effector cells and helper T cells. 
Antibodies are the secreted form of the B cell receptor for antigen and circulate in 
the blood. A single clone of B lymphocytes produces monoclonal antibodies (mAb ). 
Each Ab is composed of a variable (V) and a constant (C) region. The variable 
region is unique for each antibody and primarily responsible for antigen recognition 
and contains subregions (complementarity determining regions: CDR) that are in 
contact with the antigen. The constant region encodes the isotype of the antibody 
and thus their biological function and location (9). Ab molecules can specifically 
bind to pathogens and thereby block their access to cells or trigger the complement 
cascade by activating proteins of the complement system (10). This may eventually 
result in lysis of the target cell by forming pores in their membrane. Another 
mechanism by which antibodies mediate target cell lysis is antibody-dependent cell-
mediated cytotoxicity (ADCC) by monocytes, natural killer (NK) cells and mast cells 
(ll-13). Via binding of the Ab to the Fe receptor the effector cells are activated and 
target cells can be killed by phagocytosis and through the release of toxic granule 
components. 
The cellular immune response comprises different types of effector cells. NK cells 
and yo T cells provide early protection without the generation oflasting immunity. 
NK cells are a population oflymphocytes that was first identified by their capacity to 
kill cells without prior immunization or activation (14, 15). They secrete cytokines 
arid mediate ADCC after binding of an antibody-antigen complex to the CD16 
receptor indicating that this structure is involved in triggering of the cytolytic 
machinery ( 16, 17). In addition, they demonstrate major histocompatibility complex 
(MHC)-unrestricted killing of tumor and virally infected cells (18, 19). Their target 
cell selectivity is mediated by the use of varying combinations of different receptors 
such as CD2 and NKR-P1 for recognition and cell activation and NK receptors 
(NKR) that mediate an inhibitory function (20-22). T cells bearing yo T cell 
receptors (TCR) represent 3-10% of the total T cell population (23, 24). These yo T 
cells are mostly found in surface epithelia and mediate non-MHC-restricted 
cytolysis (25-27). Like NK cells, yo T cells express CD16 that serves as an activation 
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site for triggering cytolytic actiVIty (2S) and natural killer h;hlbitory receptorS:---
suggesting that they play a role in tumor defense similar to that suggested for NK 
cells (29). 
The major components of the cellular immune system are the "~ T lymphocytes. Via 
the "~ TCR these T lymphocytes recognize specific antigens that are processed and 
presented by MHC molecules_ T lymphocytes can be divided into 2 groups, CD4+ T 
helper and CDS+ cytotoxic T lymphocytes (CTL) recognizing Ag in the context of 
MHC class II and I respectively. The a~ TCR is expressed on the T lymphocytes in 
association with the signaltransducing CD3 complex: CD3/&, CD31-ye, I; and ~­
chains (30). The a and ~ polypeptides contain a variable, highly specific antigen 
binding region (V) and a constant region (C) that functions in transferring signals to 
the CD3 complex proteins that have cytoplasmic extensions which allow them to 
interact with signal-transducing molecules. Other molecules on the "~ 
T lymphocytes serve as important interaction structures. For activation of primary 
T lymphocytes is, besides the specific signal delivered through the TCR, a second signal 
required. This signal can be provided by interaction of the CD2S on the T lymphocytes 
with CDSO on professional antigen-presenting cells (APC) (31, 32). Furthermore, 
interaction of adhesion and accessory molecules such as CD4, CDS, CD2 and 
CD11a/CD1S on the T lymphocytes with their ligands on the target cells, i.e., MHC 
Class II and I, CDSS and CD 54, respectively contribute to T lymphocyte activation 
(33), In addition to an adhesion function, the CDS, CD2 and CD11a/CD1S 
receptors play an important role in T lymphocyte activation as costimulatory 
molecules. T lymphocytes can be activated by cross-linking of CD2, CD3 or 
CD11a/CD1S molecules without requiring specific TCRICD3 interaction with 
MHC-peptide complex (16, 20, 34-3S). Adhesion ofT lymphocytes to target cells, 
specific TCR recognition of antigen in the context of MHC and costimulation via 
accessory molecules together results in CD3 signaling, activation ofT lymphocytes 
and subsequent lysis of target cells by CTL and cytokine production by CD4 + T 
helper cells. 
lmmunogenicity of tumors 
Essential in the application of immunotherapy of cancer is that tumors must be 
recognized by the immune system_ This can only be achieved when a human tumor 
is immunogenic. Tumor immunogenicity is based on the fundamental observations 
from animal studies that tumor cells express antigens that are qualitative and/or 
quantitative different from normal cells. Specific immune recognition and rejection 
was first demonstrated in mouse experiments in which T cells recognize and reject 
secondary tumors after surgical removal of the primary tumor. These T cells 
acquired tumor-specific memory which was demonstrated by the transfer of 
protection from one animal to another by T lymphocytes (39-41)- Later, specific 
CTLs against tumor antigens have been isolated and adoptive transfer of anti-tumor 
CTL clones was found to eradicate tumor cells in animals bearing large tumors ( 42) _ 
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These findings led to the idea that individual tumor cells express tumor antigens. 
The identification of tumor antigens was made possible both by mAbs to identify 
tumor specific antigens and by the isolation and generation of T lymphocyte lines 
and clones that recognized MHC restricted tumor antigens. Already a large number 
of tumor antigens which elicit humoral and cellular reactions in tumor bearing hosts 
have been cloned and characterized (43, 44). 
Tumor associated antigens (TAA) can be classified into different groups by their 
expression pattern, which determine their suitability for immunotherapy: 
Tumor antigen "With tumor-specific expression from genes that are expressed on 
tumor cells but are silent in normal adult tissues. These genes include the MAGE 
family ( 45) which antigenic peptides are expressed on a large number of different 
tumor types (46). As the antigenic peptides are shared by tumors expressing the 
appropriate MHC type, it makes them promising targets for immunotherapy. The 
same holds true for a group of specific tumor antigens that evolved from oncogenic 
viruses. Viral proteins have been associated with human tumors and tumor-specific 
CTL can be generated in vitro ( 47). 
Tumor antigens from ubiquitous expressed genes that contain point mutations. 
Expression of these antigens is restricted to a unique mutation event and therefore 
specific for the individual tumor. Fast methods for the identification of the genes 
encoding the tumor antigens and cloning of tumor-specific T cells allow the 
development of immunotherapeutical strategies based on these individual 
mutations. 
Tumor associated antigens expressed from differentiation genes or genes that are 
overexpressed in tumors. These antigens should be used in cell-mediated 
immunotherapy with great care and expression in normal tissue needs to be 
evaluated. 
Escape mechanism of tumor cells 
Although tumor associated antigens are expressed on a variety of tumors and various 
effector mechanisms against tumor cells are present in immune system, tumors can 
escape immune recognition or fail to elicit an adequate anti-tumor immune response. 
Tumor cells can escape immune recognition by various mechanisms involving 
antigen processing and presentation, co-stimulatory signals and immuno-
modulation. 
• Antigen processing and presentation in the context of MHC class I and class II 
molecules is required for recognition by T lymphocytes. It has been observed 
that during tumor-specific immune response selection of antigen-loss variants 
could occur (48, 49). Antigenic peptides can disappear as a result of loss of 
expression of the protein or mutation of the epitopes so they can no longer be 
recognized (50). In addition, loss or reduction of MHC molecule expression 
and/or their peptide processing machinery as a result of mutations in B2-
microglobulin, transporters associated with antigen processing (TAP) proteins 
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or proteosomal LMP proteins (51, 52) may enable the tumor ~ells to escape the_, 
host immune response. 
• Even when TAA are expressed on the tumor cells there can be lack of response. 
Lack of expression of the co-stimulatory molecules CD80 on tumor cells results 
in absence of the 'second signal' during the specific binding of the TCR with Ag 
in the context of MHC and results in diminished activation ofT cells and even 
induction ofT cell anergy (53). 
• In addition to the effect on antigen presentation and T cell activation, tumor 
cells can manipulate their environment and thereby inhibit or eliminate cells 
from the immune system. A decrease in lymphocyte signal-transduction 
molecules, described in cancer patients and patients with chronic infectious 
diseases, has been proposed as a possible mechanism leading to an impaired 
immune response in cancer patients (54-56). However, these defects have 
observed to be reversed after cytokine immunotherapy or resection of the 
tumor mass (57-59). 
Immunotherapy of cancer 
The fact that tumor-specific or selective T cells and antibodies can be isolated from 
patients with a variety of different tumors has demonstrated that humoral and 
cellular immune reactions against established malignancies exist in humans. 
However, antibody treatment and adoptive transfer of these non-specific or tumor-
specific immune cells does not result in complete tumor regression in all patients 
with all kinds of tumors (60, 61). Improvement of therapy might require 
modulation of the immune response to cancer cells. Enhancement of the immune 
response against cancer can be accomplished by the modification of either the tumor 
cells or the effector cells of the immune system. Tumor cells or tumor antigens should 
be manipulated in such a way that they will become immunogenic and give rise to an 
immune response. On the other hand, manipulation of the effector cells and antibodies 
could provide effector mechanisms that circumvent escape mechanisms and therefore 
can eradicate tumor cells. 
Enhancing immunogenicity of tumors 
Vaccination of patients with tumor antigens can be a strategy to enhance the 
immune response against cancer cells. Transfection of tumor cells 'With genes that 
encode cytokines, co-stimulatory molecules or MHC molecules can enhance the 
immunogenecity of tumor cells. In experimental animal models vaccination 'With 
tumor cells that secrete lymphokines like IL-2 and GM-CSF have shown to induce 
anti-tumor T cell responses ( 62-65) and tumor cells transfected with genes encoding 
the co-stimulatory molecule CD80 have shown to enhance tumor immunity in vivo 
even resulting in immunity to rechallenge with parental, untransfected tumor cells (53, 
66). So fur vaccination with tumor cells transfected with many different cytokine and 
activation molecules have shown increased anti-tumor T cell responses and protection 
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against a subsequent tumor challenge in experimental animal studies. However, in the 
treatment of cancer patients the results were disappointing. It became apparent that 
effective induction of an immune response requires antigen presentation in an 
environment that provides appropriate help and co-stimulatory signals. Such 
conditions are provided by professional APC like dendritic cells (DC) that express 
co-stimulatory molecules and are able to efficiently activate CD4 and CDS T cells. 
Anti-tumor vaccines have been developed with DC that have been loaded or 
transfected with tumor derived peptides, proteins or whole lysates or mRNA of 
tumor cells resulting in anti tumor responses in animal model (67-70). An 
alternative strategy for inducing immunity in vivo against unidentified tumor 
antigens is the fusion of DC with tumor cells (71-73) 
All the above described vaccination strategies require the ex vivo manipulation of 
either tumor cells or DC. Protective CTL responses can also be induced by 
vaccination with tumor-specific peptides (74) or DNA encoding for these peptides 
or proteins in plasmids or viruses (75-77). Recombinant viruses and plasmids 
encoding tumor antigens can elicit specific imrnnne responses that even can be 
enhanced by the use of cytokines and co-stimulatory molecules (78, 79). 
All together, promisiog results have been obtained with a variety of vaccination 
strategies in experimental animal studies. In patients with advanced cancer, 
vaccination with tumor cells resulted often in T cell response against the vaccine and 
ouly sometimes in clinical tumor regression (80-87) 
Antibody in immunotherapy of cancer 
Antibody-mediated immunotherapy is based on the use of mAb that are reactive 
with antigens on tumor cells to activate effector immune cells at the tumor site. 
Binding of mAb to tumor antigen can activate the complement system and can 
induce ADCC by Fc-receptor-expressing cells, both resulting in destruction of the 
tumor cell (11, 12). There is a large range of antigens associated with human tumors 
that are recognized by murine antibodies. These tumor antigens can be good 
candidates for antibody-mediated immuno-therapy. Besides a cytotoxic mechanism 
induced by binding of 'naked' mAb to the tumor, the specific binding to the tumor 
makes delivery of isotopes (88), cytostatic drugs (89), toxins (90) and other 
cytotoxic agents to the tumor possible by conjugation to the mAb. 
A potential limitation of antibody therapy was expected to be the development of a 
human anti-mouse immunoglobulin immune response CHAMA), especially when 
multiple infusions are required to obtain therapeutic efficacy (91, 92). However, no 
effect of HAMA formation could be determined for the clinical response to antibody 
therapy for colorectal cancer (93, 94). 
Although antibody therapy has shown to be beneficial in animal models for renal 
cell carcinoma (95) and melanoma (96, 97), no consistent pattern of response or 
improved survival has resulted from a large number of clinical trials (98). These 
failures are often ascribed to antigenic heterogeneity and insufficient accessibility of 
cells in advanced tumors (98-100). However, more recently, promising results have 
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been obtained with 17 -!A mAb and anti-CD20 in the treatment of colon carcinoma,--
breast cancer and lymphoma (101-104). 
Ongoing research will furtber improve the therapeutical capacity of antibodies. 
Increased tumor infiltration can be accomplished by the generation of smaller single 
chain molecules consisting of only the antibody variable regions fused together by a 
flexible linker (105). Humanization of antibodies might result in reduced 
immunogenicity since only the CDR that determine the antibody binding specificity are 
of murine origin and framework regions are replaced with human framework (106). 
Furtber improvements of mAb-mediated immunotherapy might revolve from the 
generation of antibodies using phage display ( 107 -109) allowing the selection of human 
antibodies with the reqnired specificity, affinity and stability for each patient. 
Adoptive T cell-mediated immunotherapy 
Since the description of T cell growtb factor interleukin-2 it became feasible to 
culture T lymphocytes in vitro (110, 111). Activation of mouse splenocytes as well as 
human peripheral blood cells with IL-2 generates cells that demonstrate in vitro kill 
of autologous and allogeneic tumor cell lines and freshly isolated tumor cells (112-
114). 
Lymphokine activated killer (LAK) cells consist of a heterogeneous population of 
non-specific natural killer and T cells and in general display non-MHC restricted 
cytotoxicity. Adoptive transfer ofLAK cells in combination with IL-2 was capable of 
mediating tumor regression in several animal models (115-117). In humans, 
therapeutic responses have been observed in only a fraction of patients treated and 
most notable in patients with melanoma and renal cell carcinoma (4, 118-122). This 
low efficiency of LAK cells in vivo might be partly due to the lack of homing of the 
effector cells to the tumor (123, 124). Furthermore, LAK therapy was limited by the 
toxic side effects of high dose IL-2 administration (122, 125). 
A cell population that has the potential to home to tumors can be isolated from 
tumor-bearing patients (126). These tumor-infiltrating lymphocytes (TIL) can be 
expanded and can mediate regression of large metastatic tumors in a mouse model 
(127, 128). Such animal studies revealed that TIL are 50 to 100 times more effective 
in their therapeutic potency than LAK cells and display autologous tumor-specific 
cytotoxicity in contrast with the non-specific reactivity to histologically different 
tumors as described for LAK cells. Administration of TIL to autologous cancer 
patients resulted in partial responses in melanoma and renal cell carcinoma (129-
132). The in vivo tumor response correlated both with the ability of TIL to localize to 
the side of the tumor and the ability of TIL to mediate specific lysis and cytokine 
production upon culturing with tumor cells (132, 133). At present the use of LAK 
cells and TIL does not provide a satisfactory immunotherapeutical approach for 
cancer treatment. 
After the identification of tumor antigens it became possible to generate in vitro 
tumor-specific T lymphocytes (44). However, the generation of sufficient numbers 
of tumor-reactive T lymphocytes is still difficult and laborious due to the low 
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frequency of functional T lymphocytes with anti-tumor reactivity (134). Although 
still limited by the difficulties in the generation and in vitro expansion of tumor-
specific CTL, already promising results have been obtained in leukemia patients 
where treatment with leukemia-reactive T cells resulted in complete remission (135-
136) 
Targeting ofT cells to tumor cells 
Targeting T cells to the tumor can circumvent the generation of tumor specific T 
cells from individual patients and extend the anti-tumor specificity of 
T lymphocytes. The combination of tumor-selective mAb or TCR with the anti-
tumor functions ofT lymphocytes can result in an effector cell with defined anti-
tumor specificity. This can be accomplished either by bispecific monoclonal 
antibodies (bsmAb) that can bind to both tumor antigen and T lymphocytes or by 
permanent genetic grafting of T lymphocytes with tumor-selective chimeric 
receptors. 
Bispecific monoclonal antibodies 
BsmAb, with one binding site directed against a tumor antigen and the other 
recognizing an activation molecule on immune effector cells, can combine the 
advantage of antibody-specificity with the cytokine production and cytotoxic 
capacity of the effector cells (137-139). High levels of therapeutic efficacy have been 
described in several experimental tumor systems when bsmAb were used to redirect 
T lymphocytes (140-143). In a clinical study involving locoregional treatment of 
ovarian cancer patients, with bsmAb against CD3 on T cells and the folate receptor 
on the ovarian carcinoma cells, an overall anti-tumor response of 27% was observed 
(144, 145). In other clinical studies that involved infusions ofbsmAb targetedT cells 
against malignant melanoma, renal cell carcinoma, colon carcinoma and B cell 
malignancies biological responses were demonstrated (146-149). In these patients 
conjugate formation between tumor cells and activated lymphocytes soon after 
injection of bsmAb-redirected lymphocytes, elevated cytokine levels and tumor 
regression and decreased serum levels of tumor cell markers were observed. 
Although good results can be obtained in vivo using T cell retargeted bsmAb, there 
are some limitations to this approach. BsmAb-redirected CTL retain the hi-specific 
an1lbody for ouly limited periods of time (i.e., 48-96 h) due to their dissociation of the 
CTL surfuce (139, 150). Ouly in the presence of excess bsmAb, bsmAb-redirected CTI 
could recycle cytolytic activity (150). However, the excess bsmAb could evoke a human 
anti-mouse Ab response, eventually blocking cytolytic activity. Human anti-mouse 
anubody (HAMA) responses are often observed after repeated injections of bsmAb of 
murine origin and regarded as a negative effect resulting in the clearance of bsmAb 
from the circulation (91, 92, 151). However, in a clinical study involving locoregional 
treatment of ovarian cancer patients, with bsmAb, a significantly longer median 
survival probability has been observed in patients with high HAMA levels than in 
patients with lower HAMA levels (152). 
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Chimeric receptor 
The use ofbsmAb for therapy may be hampered by the inaccessibility of solid tumors to 
Ab penetration and their lintited activity (99, 150). To circumvent the lintitations 
associated with bsmAb, T lymphocytes can be genetically grafted with permanent Ab-
dictated specificity resulting in tumor-specific, MHC-unrestricted killer cells (153, 154). 
This can be accomplished by the expression on T lymphocytes of chimeric receptors 
consisting of a single chain mAb coupled to a signaltransducing molecule such as the 
Fc(s)RI y- or TCR ~-chain (155). Single chain mAb comprises the variable heavy and 
light domains of mAb fused by a flexible linker sequence and have been shown to 
display binding affinities and specificities similar to those of the natural mAb (105, 156, 
157). Chimeric receptors have been functionally expressed in mouse T cell hybridomas 
or CTL (155, 158-160), TIL (161) and human CD8+ T lymphocytes (162, 163). 
Stimulation of the chimeric receptor with the relevant target cell results in T cell 
activation responses, including cytokine production (159) and lysis of the target cell 
(155, 158, 160-164). The adoptive transfer of genetically engineered chimeric 
receptor-positive CTLs has shown in vivo anti-tumor activity in mice (165-170) 
Furthermore, gene modification ofheamatopoietic stemcells with chimeric receptors 
can protect transplanted mice from challenge with tumor cells expressing the 
relevant target antigen (171-173) The potential of the chimeric receptor approach in 
adoptive immunotherapy for cancer is currently under investigation in clinical trials. 
The application of mAb-based chimeric receptors is limited to MHC-unrestricted 
tumor antigens that can be recognized by mAb. However) many tumor antigens are 
processed intracellularly and presented as peptides in MHC molecules and therefore 
are recognized by the TCR on T lymphocytes. Tumor cells expressing these antigens 
would therefore escape mAb-based chimeric receptor recognition and escape 
destruction. For that reason, chimeric receptors have been constructed using TCR 
derived from tumor specific T cells (174-176). Efficient TCR-based chimeric 
expression and tumor cell kill and cytokine production upon tumor interaction was 
demonstrated (176). The construction of aT cell-based library ofTCR can be used to 
select in vitro TCR with increased affinities or altered affinities. Using this method, 
variant influenza A-specific TCRs have been isolated (177). Recently, the construction 
of a chimeric receptor based on a phage display selected Fab fragment specific for the 
MAGE-l peptide in HLA-Al molecules has been described. Grafting ofT lymphocytes 
with this chimeric receptor confers melanoma cells specificity resulting in specific 
tumor cell lysis and cytokine production (Willemsen, personal communication). 
Aim of this study 
Effective anti-cancer immunotherapy should be directed at the manipulation and 
enhancement of the immune capacity to fight cancer cells. In our studies we aimed 
to develop of efficient effector cells i.e. tumor-selective T lymphocytes for the 
treatment of renal cell carcinoma. By expressing antibody-binding fragments 
coupled to a signaltransducing moiety on T lymphocytes, they acquire the 
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predefined antibody specificity. In this way the specificity of tnmor selective antibodies 
can be combined with the efficacy of CTL to destroy tnmor cells. 
In chapter 2 we describe the development of a mAb-based chimeric receptor with 
renal cell carcinoma selectivity. We constructed a chimeric single chain 
innnunoglobulin/y (sCFv/y) gene composed of the variable regions of the RCC selective 
mAb G250 joined to the Fc(e)RI signaling receptor y-chain of mast cells. Retroviral 
transduction ofT lymphocytes with this chimeric receptor rendered them specific for 
renal cell carcinoma, as was shown by high levels of Ab-dictated lysis of renal cell 
carcinoma and lymphokine production upon stimulation with the relevant target oells. 
Since adhesion and accessory molecules play a critical role in T cell activation and 
effector function, we investigated the contribution of several molecules in 
T lymphocyte-tnmor cell interactions mediated by chimeric immunoglobulin receptors 
in chapter 3. Our results demonstrated a co-regulatory role for CD2, CD3 and 
CD1la!CD18 molecules in sCFv/y-mediated cytolysis indicating that intracellular 
signaling pathways of they-chain can interact with these molecules. Furthermore it was 
shown that the requirement of CD1la/CD18-CD54 adhesion interaction is dependent 
on the level of antigen on the target cells. We concluded that this might prove to be an 
important advantage for immunotherapy of tnmor cell variants that express no or low 
levels of the adhesion molecule CD54. 
Genetic engineering ofT lymphocytes for adoptive clinical innnunotherapy calls for 
efficient gene transduction methods. Therefore we developed a transient retroviral 
vector system STITCH that allows efficient transduction of human primary 
Tlymphocytes (chapter 4). This retroviral vector system STITCH in combination 
with an optimized single chain antibody chimeric receptor gene structure resulted in 
an increased chimeric receptor membrane expression on T lymphocytes. This high 
level of chimeric receptor membrane expression allowed us to investigate how the 
densities of tnmor-specific chimeric receptors and tnmor associated antigens (TAA), 
respectively, affect human T lymphocyte functions in relation to target cell 
susceptibilities to lysis. We therefore compared the level of cytolysis and cytokine 
production ofT cells with high and low level- of sCFv/y expression after interaction with 
tnmor cells with high and low TAA expression in chapter 5. We concluded that the 
expression levels of the scFv/y on the T lymphocyte and antigen on the tnmor cells both 
are important for the activation ofT lymphocytes. However, at high scFv/y receptor 
expression levels the T lymphocytes can lyse tnmor cells with a wide range of TAA 
densities. 
In chapter 6 the results are sunuuarized and the clinical application of chimeric receptor 
redirected T lymphocytes is discussed. 
The findings that are reported in this thesis demonstrate the feasibility of the chimeric 
receptor approach for the generation of innnune cells with anti-tnmor specificity. The 
first clinical trial with these redirected T lymphocytes should reveal their in vivo anti-
cancer activity. 
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----~--/ Single chain immunoglobulin/y 
gene-redirected human T lymphocytes produce cytokines, 
specifically lyse tumor cells and recycle lytic capacity 
Mo Weijtens, Ralph Willemsen, Dinko Valerio, Kees Stam, Reinder Bolhuis 
Journal of Immunology 157:836-843 (1996) 
chapter 2 
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SUMMARY~ 
To enable construction of cytotoxic T lymphocytes ( CTL) with known predefined 
antibody (Ab) specificity for adoptive immunotherapy, we constructed a chimeric 
scFv/y gene composed of the variable regions of a mAb joined to the Fc(<)Rl 
signaling receptor y-chain of mast cells. Introduction of this chimeric receptor into 
CTL rendered these lymphocytes specific for renal cell carcinoma. This approach 
combines the specificity of tumor selective antibodies with the efficacy of CTL to 
destroy tumor cells. We not only demonstrated that the transduced CTL 
functionally express the scFv/y receptor for a prolonged period of time ( 4.5 month of 
in vitro culture), but also showed high levels of Ab-dictated lysis of renal cell 
carcinoma similar to that of normal CTL, and importantly, we demonstrated that 
these CTL can recycle their lytic activity. Moreover, these scFv/y-expressing 
T lymphocytes produce cytokines upon stimulation with the relevant target cell. 
These results together with the donor independence of our gene transduction 
protocol demonstrate the feasibility of redirecting T lymphocytes for cancer 
treatment. 
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INTRODUCTION 
Adoptive cellular immunotherapy in cancer treatment refers to the transfer of 
cultured immune cells with anti-trunor reactivity into patients. Lymphokine-
activated killer (LAK) cells and trunor-infiltrating lymphocytes (TIL) have shown 
therapeutic responses in clinical trials, although these were observed in ouly a 
fraction of patients treated (122, 132). Tumor-specific MHC-restricted cytotoxic 
T lymphocytes (CTL) have been isolated, primarily specific for melanoma (178), but 
the availability of tumor-specific lymphocytes against more common types of cancer 
for adoptive therapy has been limited due to difficulties in generating these trunor-
specific CTL. Broadening of the range of trunor specificity has been obtained by 
combining biological response modifier (BRM) production, migration/homing, as 
well as lytic capacity of T lymphocytes with the selectivity of tumor-recognizing 
monoclonal antibodies (mAbs). Bispecific mAbs (bsmAb), with one binding site 
directed against a tumor antigen (Ag) and the other recognizing an activation 
molecule on the T lymphocyte, have been employed to redirect CTL in pre-clinical 
and clinical studies (139, 140, 142, 143, 145). However, the use ofbsmAb for therapy 
may be hampered by the inaccessibility of solid tumors to Ab penetration (99). 
Moreover, bsmAb-redirected CTL retain the bispecific antibody for ouly limited 
periods of time (i.e., 48-96 h) due to their dissociation of the CTL surface (139, 150). 
In addition, bsmAb-redirected CTL lose signaltransducing and, hence, lytic capacity 
following target cell recognition, lysis and T cell receptor (TCR)/CD3 complex 
clustering (!50). 
To circumvent the limitations associated with bsmAb, we and others have adopted 
an approach in which T lymphocytes are grafted with a permanent Ab-dictated 
specificity (155, 158). Variable domains of mAb fused by a flexible linker sequence 
have been shown to display binding affinities and specificities similar to those of the 
natural mAb (105, 156, 157). Such single chain antibodies (scFv) juxtaposed to a 
signaltransducing molecule such as the Fc(e)RI r- or TCR s-chain have been 
functionally expressed in mouse T cell hybridomas or CTL (155, 158-160), trunor-
infiltrating lymphocytes (161) and human CD8+ T lymphocytes (162). Stimulation 
of the chimeric receptor with the relevant target cell results in T cell activation 
responses, including BRM production (159) and lysis of the target cell (!55, 158, 
160-162). 
In this study we used an scFv/y receptor derived from a renal cell carcinoma-
selective mouse mAb G250 that is directed to a membrane-bound Ag present on 
more than 90% of primary tumors and more than 80% of metastases (179, 180). A 
chimeric gene was constructed composed of the variable domains of the G250 mAb 
and the y-chain from the Fc(e)RI receptor present on mast cells (181). Retroviral 
gene transfer was employed to successfully transduce the scFv/y into activated 
T lymphocytes. The gene-transduced T lymphocytes stably express the receptor for 
more than 4 months and specifically lyse renal cell carcinoma in an MHC-
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unrestricted manner. Continuing and advancing the work of others (155, f61), 
successful transduction was demonstrated in T lymphocytes derived from all donors 
tested, as shown by (a) scFv/y-redirected lysis, (b) cytokine production by the gene-
transduced T lymphocytes upon relevant target cell interaction, and (c) the fact that, 
like normal CTL (150, 162, 182, 183), the gene-transduced CTL can recycle their 
scFv/y-dictated lytic activity, i.e. one CTL enters into multiple lytic cycles with the 
target cells. 
MATERIALS AND METHODS 
Cells and antibodies 
PBL of healthy donors were isolated by centrifugation through Ficoll-Isopaque 
(density= 1,077 g/cm3; Pharmacia Fine Chemicals, Uppsala, Sweden) and activated 
in culture flasks precoated for 3 h at 37 'C with 1/30 dilution of OKT3 culture 
supernatant at a density of 2x106 cells/ml for 3 days in Mix-Med culture medium 
(78% RPM! 1640 buffered with bicarbonate (2 gil) and HEPES (25 mM), 20% AIM-
V (Life Technologies, Paisley, U.K.) and 2% heat inactivated human plasma 
supplemented with 360 IU/ml human recombinant IL-2 (r!L-2) (Eurocetus, 
Amsterdam, The Netherlands), 2 mM glutamine, 100 U/ml penicillin and 100 ~g/ml 
streptomycin) (8). In addition, lymphocytes were activated in Mix-Med culture 
medium with 10 ngiml OKT3 (Ortho Dia,anostic System, Beerse, Belgium) at a 
density of 0,5x106 cells/ml without r!L-2. After activation, lymphocytes were washed 
twice and cultured in Mix-Med culture medium. The following cell lines were used 
as target cells in the cytotoxicity assays: renal cell carcinoma cell lines SK-RC-7 
(kindly provided by S. Warnaar, Leiden, The Netherlands), SK-RC-52, SK-RC-1, 
SK-RC-59, SK-RC-10 (kindly provided by E. Oosterwijk, Nijmegen, The 
Netherlands), and A75 (generated in our laboratory); melanoma cell line G43 
(kindly provided by T. Boon, Brussels, Belgium); ovarian carcinoma cell line 
IGROV-1 (kindly provided by ). Benard, Villejuif, France); Burkitt lymphoma-
derived cell line Daudi; and erythromyeloid-derived cell line K562. The amphotropic 
packaging cell line PA317 (American Type Culture Collection, Rockville, MD) was 
cultured in DMEM 12501 (Life Technologies) and 10% bovine calf serum (BCS; 
Hyclone, Logan, USA) supplemented with 2 mM glutamine, 100 U/ml penicillin and 
100 ~ml streptomycin. The mAbs used in cytotoxicity inhibition studies were the 
renal tumor associated Ag (TAA)-specific G250 mAb (kindly provided by S.O. 
Wamaar, Centocor, Leiden, The Netherlands) and anti-HLA-A,B,C mAb (W6/32; 
Seralab, Sussex, U.K.). 
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Construction of scFv/ygenes 
The genes encoding the VH and the V1 domains of the G250 mouse mAb were 
isolated by anchored polymerase chain reaction (AN-PCR) (184) from eDNA 
prepared of G250 mAb-producing hybridoma cells, using anchored/anchored polyC 
primers (184) and a constant VH (HB) or V1 (KA) primer. The VH and V1 gene 
segments were cloned into the plasmid pGEMll and the nucleotide sequence was 
determined using the dideoxy-mediated chain termination method (Pharmacia, 
Uppsala, Sweden). To construct the scFv/y chimeric receptor, we used a pB!uescript 
vector containing the linker sequence 212 (156). The VH gene segment containing 
the leader sequence was reamplified using primers introducing EcoRI and BamHI 
restriction sites at the 5' and 3' ends, respectively. The V 1 gene segment was 
reamplified without the leader sequence using primers introducing Xbal and BamHI 
restriction sites at the 5' and 3' ends, respectively. The V1 gene 3' primer consists of a 
constant light chain (C1) gene sequence (18 nucleotides) and a extracellular I; gene 
sequence (nucleotides 138-158) (185). The Fc(o)RI y-chain, containing the most 3' 
9-basepair extracellular sequence in addition to transmembrane and intracellular 
sequences, was isolated from a human eDNA clone (181) using BamHI and Xbol 
restriction sites at the 5' and 3' ends (kindly provided by Z. Eshhar, Rehovot, Israel). 
To construct the chimeric scFv/y gene, V H' V 1, andy gene segments were cloned into 
the pBluescript vector. The chimeric scFvly gene was subsequently subcloned into 
the retroviral vector LXSN (186) containing the murine Moloney leukemia virus 
long terminal repeat and a neomycin resistance gene under the control of an SV 40 
promoter. The sequences of the primers used are: HB: CTC TAA GCT TGG CTC 
AAA CAC AGC GAC CTC GGA TAC AGT TGG TGC AGC; KA: CTC TTC TAG 
AGA GTC TCT CAG CTG GTA GGA TAC AGT TGG TGC AGC; VH5': CGC TCG 
AGG AAT TCG CAC TGA ACA CAG ACC; VH3': GCG CGG ATC CTG AGG AGA 
CGG TGA CTG A; V15': CTA GTC TAG AGA CAT TGT GAT GAC CGA G; V13': 
CGC GCG GAT CCA GCA GGC CAA AGC TCT GGG ATA CAG TTG GTG CAG 
c. 
Gene transduction and selection of gene-transduced lymphocytes 
The LXSN retroviral vectors were electroporated into the amphotropic packaging 
cell line PA317 using a BTX electroporator (San Diego, U.S.A.) at 250 V and 
capacitance of 750 ~F. A stable amphotropic packaging line, PA317, was obtained 
after G418 selection. The amphotropic virus supernatants produced had a viral titer 
of 1x104 colony forming units (cfu)/ml, determined on the basis of neomycin 
resistance of infected NIH-3T3 cells. To transduce the activated PBL with the G250 
scFv/y retroviral vector (L(scFv/yG250)SN), 2x106 lymphocytes were cocultivated for 
72 h with a 70% confluent irradiated (25 Gy) monolayer of virus-producing cells in 
culture medium supplemented with 4 ~ml polybrene (Sigma, St. Louis, MO, 
U.S.A.) and 360 IU/ml r!L-2. Subsequently, the gene-transduced PBL population 
was selected for 4 days in culture medium containing 1 mg/ml G418, followed by 5 
days selection in medium containing 0.4 mg/ml G418. After selection, the gene-
26 
transduced lymphocytes were expanded in round-bottom 96-well microliter plates 
(Greiner Labor Technik, Niirtingen, Germany) at 37 oc in 5% C02 in the presence 
of feeder cells: irradiated (25 Gy) allogeneic PBL and Epstein Barr Virus transformed 
lymphoblastoid B cell lines (B-LCL) as described previously (7, 187). Cloning of 
gene-transduced T lymphocytes was accomplished through limiting dilution by 
seeding these T lymphocytes in round-bottom 96-well microliter plates at 10, 3, I 
and 0,3 cells/well in the presence of feeder cells (7). The culture medium was RPM! 
1640 buffered with bicarbonate (2 gil) and HEPES (25 mM; Life Technologies), 
supplemented with 10% (v/v) human plasma, 150 IU/ml r!L-2, 4 mM glutamine, 
100 U/ml penicillin, 100 ~g/ml streptomycin, I ~ml PHA (Murex Diagnostics, 
Dartford, U.K.). 
Polymerase chain reaction (PCR) 
DNA was isolated from 105 PBL by incubation of the samples in DNA lysisbuffer (50 
mM Tris-HCl (pH 9,0), 50 mM KCl, 7 mM MgC!,, 0,5% l'.'P-40, 0,5% Tween-20, 60 
~ml proteinase K) at 55 oc for 60 min. Proteinase K was inactivated at 95 oc. DNA 
from 104 cells was amplified using the 5' V, primer (CTAGTCTAGAGACAT-
TGTGATGACCCAG) and 3' y primer (GCTGCTCGAGTCTAAAGCTACTGTGG-
TGG). The PCR reaction was performed in a total volume of 50 ~ containing 50 
mM Tris-HCl (pH 9,0), 50 mM KCl, 7 mM MgCl,, 200 ~of each dNTP, 20 pmol 
of each primer and 0,25 U Super Taq (HT Biotechnologies, Cambridge, U.K.) and 
was covered with 50~ of paraffin oil. The samples were amplified in 35 cycli (30 sat 
95 oc, 30 s at 58 oC, and I min at 72 oq using a Trio Thermoblock (Biometra, 
Gottingen, Germany). Twenty microliters of each sample was analyzed by agarose 
gel electrophorese. For RT-PCR, RNA was isolated from 4x106 PBL using the 
RNeasy kit (Qiagen, Hilden, Germany). Single strand eDNA was synthesized by 
incubation of RNA with 500 ng oligo d(T) primer (Promega, Leiden, The 
Netherlands) for 10 min at 75 oc, followed by incubation at 37 oC for 60 min with 
100 U of Superscript (Life Technologies), 50 mM Tris-HCl (pH 8,3), 40 mM KCl, 6 
mM MgCl2, 10 mM DTT (Life Technologies), 500 ~ dNTP and 13 U RNAguard 
(Pharmacia, Uppsala, Sweden). PCR was subsequently performed on DNA from 105 
cells as described above. As a control for eDNA synthesis, amplification with ~2-
microglobulin primers was performed. Sequences of the ~2microglobulin primers 
are: ~2m 5': TCAGGTTTACTCACGTCATCCAG, and ~,m 3': TCACTCAATCCAA-
ATGCGGC. 
Measurement of cytokine production 
To determine cytokine production by gene-transduced PBL upon Ag stimulation, 
6xl04 transduced PBL were cultured for 24 h in either the presence or absence of 
2xl04 adherent tumor cells in RPM! culture medium containing 360 IU/ml r!L-2. 
Plates were centrifuged for 5 minutes at 1500 rpm, supernatant was harvested, and 
levels of TNFu and GM-CSF were measured by ELISA (Medgenix Diagnostics, 
Fleuris, Belgium) according to suppliers' specifications. 
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Cytotoxicity assay 
Cytotoxic activity was measured in a 4- to 5-h 51Cr-release assay. Briefly, varying 
numbers of effector cells were added in triplicate to 96-well round-bottom 
microtiter plates (100 ).ll/well), followed by addition of2500 target cells (100 !J})/well. 
The target cells were labeled with 100 ~Ci 51Cr/0.5x106 cells for 2 h at 37 oc. At the 
end of the 4- to 5-h incubation period (37 oc and 5% C02), supernatants were 
collected using a Skatron harvesting system (Skatron, Lier, Norway), and 
radioactivity was counted in a gamma-counter. The percent specific lysis was 
calculated as follows: ((test counts - spontaneous counts) I (maximum counts -
spontaneous counts)] x 100%. In blocking experiments, G250 mAb (10 ~ml) or 
W6/32 mAb (10 ~ml) was added to labeled target cells !5 to 30 minutes before 
addition of the effector cells. 
CTL-target cell interactions 
To examine lytic recycling capacity of scFv/y-transduced CTL, a secondary 
cytotoxicity assay that we previously developed was used (150). In short, CTL (3x!05 
or lx105) were incubated for 18 h in the presence or the absence of adherent target 
cells (3x!05) in I ml of medium supplemented with 360 IU/ml r!L-2. After exposure, 
transduced PBL were harvested, counted, and subsequently tested for lytic activity in 
the 51 Cr release assay as described above. Target cell contamination was determined 
by phase contrast microscopy. 
RESULTS 
Cytokine secretion by G250 scFv/y-transduced T lymphocytes upon 
stimulation with renal cell carcinoma 
For expression of scFv/y receptors selective for renal cell carcinoma we constructed 
one continuous molecule comprising gene segments of the variable region of the 
renal cell carcinoma-selective mouse mAb G250 and the signaltransducing human 
Fc(z)RJ y-chain transmembrane and intracellular region. Retroviral gene transfer 
using the LXSN vector was used to generate stable integration into the genome, as 
we and others have previously shown to be effective in human activated 
T lymphocytes (188, 189). Gene transduction of activated human PBL was 
accomplished after cocultivation of anti-CD3-activated human PBL (frozen/thawed) 
with irradiated virus-producing packaging cells followed by selection in G418-
containing medium and expansion in the presence of feeder cells for 2 weeks. The 
presence of the scFv/y viral construct in the genomic DNA of scFv/y-transduced 
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T lymphocytes and the expression of scFv/y mRNA were demonstrated by- DNA-~:. 
PCR and RT-PCR using scFv/y-specific primers (fig. 2.1lanes 4-9). 
Chimeric receptor surface expression was too low to be detected by FACS with anti-
idiotype mAb (190); therefore, the percentage of scFv/y-transduced T lymphocytes 
could not be determined. To examine functional expression of the receptor, the 
ability of scFv/y-transduced T lymphocytes to secrete GM-CSF and TNF-cx after 
specific target cell interaction was tested (table 2.1). ScFv/y-transduced bulk 
T lymphocytes specifically secreted GM-CSF and TNF-cx after interaction with A75, 
a G250 mAb-binding renal cell carcinoma cell line, but not after stimulation with 
irrelevant SK-BR-3, a breast carcinoma cell line, thereby showing functional 
expression of the scFv/y receptor and specific recognition of the relevant target cells 
by the scFv/y receptor. 
Cytolytic activity of G250 scFv/"ttransduced bulk CTL 
To further study the functional expression of the scFv/y receptor on transduced 
T lymphocytes, cytolytic activity against a panel of renal and nonrenal cell 
carcinoma lines was evaluated in a 51Cr release assay (fig. 2.2). High levels of lysis 
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figure 2.1 PCR analysis of the detection of scFv/y G250 DNA and RNA in transduced T lymphocytes 
derived from different donors. Ethidium bromide stained gel of DNA~PCR amplification products 
obtained using primers specific for scFv/y G250 (A), RT~PCR amplification products using primers 
specific for scFv/y G250 (B), and RT-PCR amplification products using ~2-microglobulin primers (C). 
lane 1, Positive control for scFv/y G250-spedfic primers: retroviral vector containing the scFv/y G250 
construct; 2, negative control (no DNAJRNA control); 3, mock-transduced PBL (PBL-LXSN); 4, scFv/y-
transduced PBL (PBL-scG250); 5, scFv/y-transduced T lymphocytes derived from different donors: VD-
2; 6, VD-3; 7, VD-4; 8, VD-5 and 9, VD-9. The marker (M) is a 100 bp ladder. 
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(±80% at an E/T ratio of 60) were shown against all G250 mAb-binding renal cell 
carcinoma cell lines. No lysis was observed of control cell lines SK-RC-59, a G250 
mAb-nonbinding renal cell carcinoma cell line, and G43, an irrelevant melanoma 
cell line ( <20% at an E/T ratio of 60). In addition, no MHC-unrestricted natnral 
killer activity (NK) or activated kill (AK) activity was found, as shown by the 
absence oflysis ofK562 and Daudi, respectively (fig. 2.2). That indeed the specificity 
of lysis was dictated by functional expression of the scFv/y gene was further 
demonstrated by the inhibition of renal cell carcinoma lysis following the addition 
of soluble G250 mAb to the renal cell carcinoma target cells (fig. 2.2). No inhibition 
of lysis was seen with the control anti-HLA-A,B,C Ab (W6/32; data not shown). 
These combined results demonstrate (a) the specificity of the G250 mAb-mediated 
inhibition of lysis, and (b) the non-MHC-restricted nature of the scFv/y receptor 
interaction with the target cell. Retroviral transduction has been shown to introduce 
foreign genes stably into lymphocytes without adversely affecting their functions 
over time ( 189 ). Here, we demonstrate stable functional expression over a test 
period of more than 4.5 months of continuous culture by serial cytotoxicity studies. 
During this culture period we repeatedly observed specific lysis of renal cell 
carcinoma by bulk-cultured, gene-transduced CTL. This scFv-redirected CTL lysis 
was ouly inhibited by renal carcinoma -specific G250 mAb and was devoid of NK 
and AK activity. With time, an increase in CD4+ T lymphocytes in the bulk 
population (>25%) was observed, paralleled by a decrease in specific lytic activity. 
Depletion of CD4+ lymphocytes with magnetic beads completely restored lytic 
activity up to the level observed before the preferential outgrowth of CD4+ 
lymphocytes (fig. 2.3). 
This result demonstrates that CD4+ lymphocytes are not lytic and that the decline in 
the percentage of CDS+ CTL in favor of CD4+ T lymphocytes accounts for the 
observed decrease in scFvfr-mediated target cell lysis. CD4+ lymphocytes do produce 
cytokines upon scFv/y-mediated specific target cell interaction. Compared with the 
CDS+ scFv/y-transduced T lymphocytes, CD4+ T lymphocytes produce 
approximately 5.5-fold the amount of GM-CSF and about 1.6-fold the amount of 
TNF-o: (data not shown). 
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table 2.1 GM~CSF and TNF-o: secretion of transduced PBL upon target cell interaction~ 
effector 
PBL-scG250 
PBL-LXSN 
103 
99 
GM-CSF 
A75 
1326 
<25 
SK-BR-3 
64 
38 
<12 
<12 
TN F-a 
A75 
192 
<12 
SK-BR-3 
13 
<12 
"Six times 104 T lymphocytes transduced with scFv/y (PBL~scG250) or mock-transduced (PBL~LXSN) 
were cultured in medium or with 2 x 104 G250 mAb~binding or nonbinding tumor cells, for 24 h. 
Cytokine secretion in supernatant was measured by ELISA (Medgenix, Brussels, Belgium). Background 
cytokine secretion by tumor cells alone has been subtracted (GM~CSF: 78 pg/ml for A75 and 46 pg!ml for 
SK-BR~3; TNF-a: <12 pg/ml for A75 and SK~BR-3). Production of GM-CSF and TNF~et is in pg!ml/3 x 
105 cells/24 h. A75 is a G250 mAb~binding human renal cell carcinoma cell line. SK-BR-3 is a human 
breast carcinoma cell line used as G250 mAb nonbinding control cell line. Similar results were obtained 
from three independent experiments. - = no stimulator cells. 
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figure 2.2 Cytotoxicity of scFv/y (PBL-scG250) and mock (PBL-LXSN)-transduced T lymphocytes against 
G250 mAb-binding and nonbinding cell lines. scFv/y~transduced (PBL~scG250) or mock~transduced 
(PBL~LXSN) lymphocytes were incubated with the follo-wing target cells: A75, SK-RC-1, SK-RC-7, SK-
RC~10, SK-RC-52 (G250 mAb-binding renal carcinoma cell lines), SK-RC-59 (G250 mAb nonbinding 
renal carcinoma cell line), G43 (G250 mAb nonbinding melanoma cell line), 1<562 and Daudi, and tested 
in a 5-h cytotoxicity assay. Blocldng of cytolysis with G250 mAb was performed at a concentration of 10 
Jlg/ml. The specific 51 Cr release is depicted at different Err ratios. Experiments were performed in 
triplicate and the standard deviation did not exceed 10%. Similar results were obtained from at least two 
independent experiments. The percentages of spontaneous release were for A75, 22%; SK-RC~1, 23%; SK-
RC-7, 16%; SK-RC-10, 40%; SK~RC~52, 12%; SK-RC-59, So/o; G43, 12%; 1<562, So/o; Daudi, 14%. 
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Cytolytic activity of G250 scFvlttransduced T lymphocyte clones 
Limiting dilution of the CTL from the transduced bulk culture yielded CTL clones 
with multiple lytic activities. When cloned scFv/y-transduced CTL were tested for (a) 
G250 scFv/y-redirected lysis (target: SK-RC-7), (b) NK (target: K562), and (c) AK 
activity (target: Daudi), the following picture emerged: two clones with only scFv/y-
dictated lytic activity (clones 44 and 75); a clone with scFv/y-dictated specificity and 
NK lytic activity (clone 27); 2 clones with scFv/y, NK and AK activity (clones 45 and 
49); and a clone without cytolytic activity against the targets tested (clone 41; fig. 
2.4). 
These differences in target cell specificities among CTL clones and hence CTL target 
recognition structures were also illustrated by the fact that only lytic activities of 
those CTL clones that exclusively lysed renal cell carcinoma (scFv/y dictated) were 
completely inhibited by G250 mAb. The cytolytic activity of cloned scFv/y-redirected 
CTL that also exerted NK and/or AK activities was partly inhibited (fig. 2.4). Clones 
27, 41, 45 and 49 were phenotyped and found to be TCRa~+ and CDS+. Two clones 
(41 and 49) were further analyzed and were negative for CD16 and± 50% of the 
T lymphocytes expressed CD 56. In addition, no scFv/y G250 membrane expression 
could be detected by FACS using anti-idiotype mAb (190) (data not shown). 
effector cells %CD4 %CD8 % 51Cr release 
PBL~scG250 48 52 
PBL-scG250 CD4 depl 0 97 
PBL-scG250 CD8 depl 97 3 
PBL 8 92 
0 20 40 60 80 100 
figure 2.3 Cytotoxicity of sCFv/y (PBL-scG250), CD4-depleted fraction (PBL-scG250 CD4 depl), COS-
depleted fraction (PBL-scG250 CDS depl) and untransduced PBL against G250 mAb-bind.ing renal cell 
carcinoma, A75. CD4- and COS-depleted PBL-scG250 fractions were obtained by magnetic bead 
depletion of either population of the bulk culture. The percentage of CD4+ or cos- T lymphocytes was 
determined by flow cytometry. Specific 51 Cr release is depicted at an E/T ratio of 60. Experiments were 
performed in triplicate and the standard deviation did not exceed 10%. Similar results were obtained 
from at least two independent experiments. The percentage of spontaneous release was 90,6. 
Efficacy of functional LXSN scFv/y gene transduction protocol 
To investigate whether scFv/y transduction and subsequent functional expression by 
recipient T lymphocytes is donor independent, we set out to transduce fresh 
T lymphocytes from 10 healthy volunteers. Activated PBL were cocultivated and 
selected as described. Evaluation of genomic DNA and RNA by PCR analysis showed 
T lymphocytes from all donors to contain and to transcnbe the fusion gene (fig. 2.1 
lanes 5-9). Subsequent analysis of functional expression demonstrated a complete 
correlation between the presence of scFv/y transcripts and (a) GM-CSF and TNF-a 
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production upon Ag stimulation (table 2.2) or (b) scFv/y-mediated target cell lysis 
by the CDs• scFv/y-transduced CTL (fig. 2.5). Cytokine production was observed in 
all10 gene-transduced T lymphocyte cultures. Specific lysis of renal cell carcinoma 
was shown, with 8 of 10 scFv/y-transduced T lymphocyte cultures derived from 10 
donors. Specificity was further demonstrated by inhibition of renal cell carcinoma 
lysis by soluble parental G250 mAb to the target cells before addition of the scFv/y-
expressing CTL. To exclude the possibility that lysis might involve HLA molecules 
on the target cells, lysis of renal cell carcinoma by these transduced T lymphocytes 
derived from five different donors was also tested by preincubation of the target cell 
with anti-HLA framework Ab W6/32. No inhibition oflysis was seen. 
PBL-LXSN 
PBL-scG250 
clone27 
clone41 
clone44 
clone45 
clone49 
clone75 
0 60 120 
% 51 Cr release 
target cells 
•SK-RC-7 
EaSK-RC-7+G250 
DDaudi 
!0 K562 
figure 2.4 Cytotoxicity ofT lymphocyte clones obtained by limiting dilution of a scFvly~transduced PBL 
population. T lymphocyte clones were tested in a 5-h 51Cr release assay with target cells: K562, Daudi or 
the renal carcinoma cell line SK-RC-7. Blocking of cytolysis was achieved with G250 mAb at a 
concentration of 10 ).lg/ml. The E/T ratio was 20. PBL-scG250 is the scFv/y-transduced bulk population 
and PBL-LXSN is the mock-transduced population. E>.:periments were performed in triplicate and the 
standard deviation did not exceed 15%. Similar results were obtained from at least tvvo independent 
experiments. The percentages of spontaneous release were SK-RC-7, 13%; Daudi, 17%; K562, 9%. 
As cytokine production is another sensitive method to measure specific CTL/target 
cell interactions, we assume that the percentages scFv/y-transduced T lymphocytes in 
the two nonlytic cultures are too low to monitor lysis. Differential efficacies of gene 
transduction and subsequent selection of gene-transduced lymphocytes will result in 
T lymphocyte bulk populations comprising different percentages of gene-transduced 
T lymphocytes. In addition, T lymphocyte composition will vary among cultures of 
individual donors. This may explain the different levels of cytolytic activity and the 
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different lytic activities (e.g. scFv/y-dictated lysis and NK/AK activity) as well as 
differences in the lymphokine repertoire. 
G250 scFv/y-transduced T lymphocytes recycle chimeric receptor-dictated 
lytic activity 
To examine the capacity of gene-transduced CTL to recycle their scFv/y-redirected 
cytolysis, these CTL were allowed to enter multiple lytic interactions with relevant 
target cells before being tested in a secondary 51Cr release assay (ISO). ScFv/r-
transduced CTL were added to an equal (1/1) or excess (1/3) number ofuulabeled 
G250 mAb-binding renal cell carcinoma A75 cells and incubated for 18 h. During 
the incubation period more than 95% and 60% of the target cells were lysed, 
respectively, as determined under the phase contrast microscope. Unlabeled, 
irreleVant ovarian carcinoma cells (IGROV-1) were used as control target cells and 
were not lysed by the effector cells. ScFv/y-transduced CTL were harvested and 
tested for lytic activity in a secondary cytotoxicity assay in the presence of 51 Cr 
labeled A75 cells. These preincubated cells still displayed scFv/y-dictated cytolytic 
activity, which suggests that these cells, although we cannot formally exclude 
recruitment, retain full lytic recycling capacity (fig. 2.6). 
table 2.2 GM~CSF and TNF-a secretion of transduced PBL upon target cell interactionu 
GM-CSF TN F-a 
effector A75 IGROV-1 A75 IGROV-1 
VD-1 <12 716 <12 16 509 66 
VD-2 <12 1500 <12 <12 1131 66 
VD-3 <12 2614 <12 <12 940 52 
VD-4 232 445 96 54 46 19 
VD-5b <12 153 <12 36 85 28 
VD-6 <12 2709 <12 16 1260 56 
VD-7 <12 329 <12 <12 127 16 
VD-8 <12 902 <12 24 516 58 
VD-9 <12 743 <12 <12 1800 <12 
VD·10 <12 691 <12 <12 438 <12 
PBL·LXSN <12 31 <12 <12 <12 <12 
"Six times 104 T lymphocytes transduced with scFv/y (VD-1-10) or mock-transduced (PBL-LXSN) were 
cultured in medium or with 2 x 104 G250 mAb-binding or nonbinding tumor cells, for 24 h. Cytokine 
secretion in supernatant was measured by ELISA (Medgenix, Brussels, Belgium). Background cytokine 
secretion by tumor cells alone has been subtracted (GM-CSF: 206 pg!ml for Ai5, <12 pg/ml for 
IGROV-1; TNF-a.: 22 pg!ml for A75, 47 pg/ml for IGROV~l). Production of GM~CSF and TNF~tX is in 
pg/ml/3 x 105 cells/24 h. A75 is a G250 mAb~binding human renal cell carcinoma cell line. IGROV~l is a 
human ovarium carcinoma cell line used as G250 mAb nonbinding control cell line. Similar results were 
obtained from two independent experiments. ~ = no stimulator cells. bGM-CSF and Tl\i'F-!X in pg/ml/5 x 
105 cells/24 h. 
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figure 2.5 Cytotoxicity of scFv/y-transduced CTL derived from 11 different healthy donors (VD-1-10 and 
PBL-scG250) and mock-transduced (PBL-LXSN) PBL against G250 mAb-binding renal carcinoma cells, 
A75. Gene-transduced T lymphocytes were depleted for CD4+ T lymphocytes and incubated with A75, 
K562, or Daudi as target cells in a 4- to 5-h cytotoxicity assay. Blocking of qtolysis was achieved with 
G250 mAb at a concentration of 10 ).lg/ml. The specific 51Cr release is depicted at E/T ratio of 60 or 20 (""). 
E:...'Periments were performed in triplicate and the standard deviation did not exceed 15%. The 
percentages of spontaneous release were: A75, 13%; Daudi, 6%; K562, 5%. 
DISCUSSION 
In this report we have demonstrated redirection of human T lymphocyte specificity 
by retroviral single chain immunoglobulin/y gene transfer, obtaining CTL with a 
permanent, MHC-unrestricted, tumoricidal activity. Redirection of lymphocyte 
specificity to recognize targets not recognized by their endogenous TCR was 
previously achieved with bsmAb, one arm of which is directed against a tumor Ag 
and the other against an activation molecule on T lymphocytes (139, 140). Such 
bsmAb-redirected CTL have shown in vivo anti -cancer activity in mice ( 142, 143) 
and in man (144-146). Lysis of tumor cells can be attributed to bsmAb-redirected 
CDS+ T lymphocytes, although in mice additional anti-tumor growth effects were 
seen due to cytokine release by CD4+ T lymphocytes and subsequent activation of 
CTL and NK activities (191). Loco-regional immunotherapy in clinical studies has 
shown tumor responses that were restricted to the treated area (144, 145). This may 
be due to limited migration capacity of bsmAb-redirected CTL and their limited 
recycling of signal transducing capacity, as we reported previously (150). 
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figure 2.6 Cytolytic recycling capacity of scFv/r~transduced PBL (PBL-scG250). Gene-transduced PBL 
were first exposed for 18 h to (a) medium alone, (b) G250 mAb-binding renal cell carcinoma, A75, or {c) 
irrelevant ovarian carcinoma cells, IGROV-1. E/T ratios were 1 and 0.3. After exposure to the target cells, 
retention of the cytolytic capacity of the transduced PBL vvas measured in a 4-h 51 Cr release assay against 
renal cell carcinoma, A75. E/T ratios were 5, 10, 20 and 40. Experiments were performed in triplicate and 
the standard deviation did not exceed 15%. Similar results were obtained from at least two independent 
e.xperiments. The percentage of spontaneous release was 9%. 
Genetic engineering ofT lymphocytes using an scFv/y gene carrying LXSN retroviral 
vector resulted in permanently acquired, Ab-dictated target cell specificity and lysis 
as well as the triggering of lymphokine production and of MHC-unrestricted 
NK/AK lysis. Such scFvfr-redirected CTL show normal recycling oflytic activity and 
may have normal migration and target cell homing capacities. Indeed, we 
demonstrated that G250 scFvfr-transduced CTL show relevant renal cell carcinoma-
specific kill and prolonged functional expression of the chimeric receptor for a test 
period of almost 5 months. Although transcription of the fusion gene could be 
demonstrated, levels ofT lymphocyte surface expression were too low for detection 
by FACS analysis. Despite this low surface expression, the observed levels of lytic 
activities of scFv/y-transduced CTL was high (e.g. 76% for clone 44 at an E/T ratio of 
2) in a 5-h 51Cr release assay. This high lytic activity may be explained by the high 
affinity of the scFv/y chimeric receptor relative to that of TCR for the Ag on the 
target cells, although we expect the affinity of scFv/y to be lower than the parental 
mAb. This low expression of scFv/y receptors may prove advantageous from a 
clinical point of view, as it might lower the human anti-mouse Ab responses in 
patients after transfusion of scFv/y-expressing CTL 
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Because the number of tumor cells is usually in excess of lymphoid effecto~ cell 
number, their elimination by CTL in vivo requires that individual CTL recycle their_. <· 
lytic machinery. We previously demonstrated that only in the presence of excess 
bsmAb, bsmAb-redirected CTL could recycle cytolytic activity (150). However, the 
excess bsmAb evoked a human anti-mouse Ab response, eventually blocking 
cytolytic activity (91, 92, 145). We, therefore, studied the lytic recycling capacity of 
scFv/y-transduced CTL. Prolonged exposure (18 h) of scFv/y-transduced CTL to 
their specific target cells and subsequent testing of these CTL in a secondary 
cytotoxicity assay demonstrated their capacity to enter multiple lytic cycles with 
their specific tumor targets. In normal CTL, the continued triggering of 
T lymphocytes and, hence, recycling of lytic capacity require continuous synthesis 
and subsequent surface expression of endogenous TCR (150, 192, 193). Therefore, 
we conclude that scFv/y gene-transduced CTL, which functionally express the scFv/y 
chimeric receptor and show recycling of lytic capacity, also continuously synthesize 
the transduced chimeric receptor. 
Clinical application of scfv/y-redirected PBL can be effective as it combines 
induction ofBRM production and cytolysis by the redirected T lymphocytes. Release 
of lymphokines by CD4+ gene-transduced T lymphocytes upon specific target cell 
interaction may also contribute to tumor growth inhibition as well as induction of 
NK/ AK activities. These lytic activities may result in elimination of those tumor cells 
that lack or downregulate the relevant TAA expression (122). 
An important feature of CTL expressing scfv/y receptors is that they, like Ab per se, 
recognize Ag in an MHC-unrestricted manner. Hence, in contrast to T lymphocytes 
which recognize their ligand via their endogenous MHC-restricted TCR, the scFv/y-
dictated specificity and anti-tumor activity is not adversely affected by tumor cells 
that down-regulate their MHC complex or for other reasons do not eJq>ress MHC-
restricted Ag (194). 
In conclusion, we have shown long term functional expression of scFvfr chimeric 
receptors by transduced T lymphocytes, scfv/y-triggered lymphokine production, 
and cytolysis of relevant target cells as well as recycling of lytic activity. The scfv/y 
gene transduction was successful in all 11 donors and these results provided 'proof 
of principle' of the use of scFv/y-expressing CTL for clinical anti-cancer treatment. 
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SUMMARY 
Adhesion and accessory molecules play a critical role in T cell activation and effector 
function in general and in tumor cell recognition and lysis in particular. We 
investigated the contribution of CD2, CD3, CDl!a/CD18, CD54 and CD58 
molecules in T lymphocyte-tumor cell interactions mediated by chimeric 
immunoglobulin receptors. The chimeric receptor is composed of a single chain 
antibody binding site and a y-chain signaltransducing molecule (scFv/y). 
T lymphocytes expressing such scFv/y receptors recognize the G250 antigen (Ag) on 
renal cell carcinoma (RCC) in a major histocompatibility complex (MHC)-
unrestricted manner and exert RCC selective cytolysis. A coregulatory role for CD2, 
CD3 and CDl!a/CD18 molecules in scFv/y-mediated cytolysis was demonstrated 
using monoclonal antibody (mAb )-induced inhibition of scFv/y-mediated cytolysis. 
The inhibition of lysis was not due to inhibition of cytotoxic T lymphocyte ( CTL)-
target cell conjugation but rather to a post-conjugate signaling event. Binding of 
CD 54 and CD 58 mAbs to the RCC did not inhibit cytolysis of RCC that expressed 
high levels of both CD54 and the G250 Ag (A75), whereas cytolysis of RCC 
expressing intermediate levels of CD54 and G250 Ag (SK-RC-17 cl.4) was partly 
inhibited by the CD 54 mAb. Binding of low concentrations of G250 mAb to RCC 
(A75) rendered these cells sensitive to CD54 mAb inhibition, demonstrating a direct 
functional relation between G250 Ag expression level and adhesion molecules. 
Taken together, our findings indicate a coregulatory role for CD2, CD3 and 
CD11a/CD18 molecules in the scFv/y-mediated cytolysis of tumor cells and show 
that the requirement of CD11a/CD18-CD54 interactions is dependent on the level 
of free Ag. This makes these gene-transduced T lymphocytes attractive tools for 
adoptive immuno-gene therapy of cancer. 
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INTRODUCTION 
T lymphocytes recognize their target cells via the T cell receptor (TCR). Interaction of 
CTL with target cells reqtrires specific recognition of the TCR with Ag in the context of 
MHC molecules resulting in CD3 sigoaling, activation and subsequent effector 
functions ofT lymphocytes. This specific target cell recognition is preceded by non-
specific conjugate formation, primarily mediated by non-polymorphic cell-surface 
receptors such as CD4, CDS, CD2 and CD11a/CD1S on the T lymphocytes with their 
ligands on the target cells, i.e., MHC Class II and I, CD5S and CD 54, respectively (33, 
195). In addition to an adhesion function, the CDS, CD2 and CD11a/CD1S receptors 
play an important role in T lymphocyte activation as costimulatory molecules. 
T lymphocytes can be activated by cross-linking of CD2, CD3 or CD11a/CD1S 
molecules without requiring specific TCR/CD3 interaction with MHC-peptide complex 
(16, 20, 34-3S). A coregu!atory role in anti-CD3 and anti-CDl6 mAb-induced 
activation has also been demonstrated for CDl!a!CDlS (36, 37, 196). Adhesion of 
T lymphocytes to target cells, specific TCR recognition of Ag and costimulation via 
accessory molecules together results in triggering of, e.g., the lytic machinery and 
subsequent lysis of target cells. 
Cancer-specific CTL, particularly in melanoma, can be used for immunotherapy as 
tumor cell killers (132). These cancer-specific T lymphocytes for most tumors are 
difficult to obtain and to expand in tissue culture. To circumvent this reqtrirement for 
tumor-specific CTL, CD3""' T lymphocytes can be selectively activated by anti-CD3 
mAb ( 16, 197) and their cytolytic effector function can be directed against a predefined 
target specificity using bispecific mAb (bsmAb) with two distinct binding sites, one for 
the CD3 complex and the other for a tumor-associated Ag (TAA) (l3S-140, 145). 
Binding of the bsmAb to both the CD3 complex and the TAA results in triggering of 
cytokine-producing capacity and of the cytolytic effector function of the CTL. In this 
high affinity interaction the CD11a/CD1S-CD54 adhesion pathway and the CD2-CD5S 
pathway are also involved in both adhesion and coregulation of bsmAb-mediated 
cytolysis (37, 19S, 199). Another approach to redirect the specificity of CTL is the 
permanent grafting of these cells with mAb-dictated specificity. This can be realized by 
genetic engineering of CTL to express an1J.body-based chimeric receptors (scFv/y) in 
their membrane (154, 155, 161-163). These chimeric receptors comprise the Ag binding 
part of mAb and the sigoaltransducing y-chain of the high affinity Fc(e)RI (1S1) that 
can function independently of CD3 complex (200, 201). We previously showed that 
such scFv/y-transduced CTL can (a) specifically lyse target cells via their scFv/y chimeric 
receptor in a MHC-unrestricted manner, (b) produce cytokines upon specific target cell 
interaction, and (c) like normal CTL (150), these gene-transduced CTL recycle their 
scFv/y-dictated lytic activity (163). 
Interactions between TCR-antigen complex and activation or accessory molecules, as 
well as a role for adhesion molecules in T lymphocyte-target cell conjugate formation 
have been described for MHC-restricted, TCRa~-mediated activation ofT lymphocytes 
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(35). We also demonstrated these functional interaction to occur with the TCR-
complex in situations where activation took place via bsmAb involving antigen 
recognition in a MHC-unrestricted way (36, 37). In both cases, coactivation/adhesion-
ligand interactions result in enhanced activation ofT lymphocytes. This T lymphocyte 
activation occurs either through interaction of the intracellular signaling pathways of 
coactivation receptors on the one hand and the TCR/CD3 complex on the other, 
involving &je- and ;;-chains or via enhanced effector-target cell binding. The question we 
wanted to address is whether such interactions also occurred between the intracellular 
signaling pathways of coactivation molecules and a chimeric receptor consisting of a 
tumor-specific single chain antibody linked to they-chain of the Fc(e)RI. 
In this study, we show that CD3, CD2 and CD11a/CD18 on the scFv/y-re<lirected CTL 
can act as accessory molecules in the lytic process. We also show that the contribution 
of CD11a/CD18-CD54 interaction in the cytolytic process depends on the expression 
level of TAA on the tJ.uget cell. High numbers of G250 Ag on the tJ.uget cell bypass the 
requirement of CD!la/CD18-CD54 interaction for scFv/y-mediated T cell cytolysis. 
These findings pave the way for clinical anti-tumor therapy using scFv/y gene-
transduced T lymphocytes. 
MATERIALS AND METHODS 
Cells and antibodies 
Peripheral blood mononuclear cells (PBMC) of healthy donors were isolated by 
centrifugation through Lymphoprep (d=1,077 glcm') (Nycomed, Oslo, Norway) and 
activated in Mix-med culture medium (78% RPMI 1640 buffered with bicarbonate (2 
gil) and HEPES (25 mM), 20% AIM-V (Gibco BRL, Paisley, England), 2% heat-
inactivated human serum, 2 mM glutJ.unine, 100 U/ml penicillin and 100 ll1lfml 
streptomycin) (8) with 10 ng/ml OKT3 (Ortho Diagnostic System, Beerse, Belgium) at 
a density of O.Sx106 cells/mi. After 3 days activation, lymphocytes were washed and 
cultured in RPM! culture medium (RPM! 1640 buffered with bicarbonate (2 gil) and 
HEPES (25 mM), 10% heat inactivated human serum, 2 mM glutJ.unine, 100 U/ml 
penicillin and 100 ll1lfml streptomycin) supplemented with 360 IU/ml human 
recombinant IL-2 (riL-2) (Chiron, Amsterdam, The Netherlands). The following cell 
lines were used as tJ.ugets in cytotoxicity assays and conjugate assays: RCC A75 
(generated in our laboratory), SK-RC-17 cl.4 (G250 Ag eDNA transfected RCC cell 
line)(kindly provided by E. Oosterwijk, Nijmegen, The Netherlands) and lgR39 
melanoma cell line (kindly provided by L. de Ley, Groningen, The Nether lands). The 
antibodies used for FACS staining and cytotoxicity and conjugate inhibition studies 
were: renal tumor associated Ag (TAA)-specific G250 mAb (kindly provided by S. 0. 
Warnaar, Centocor, Leiden, The Netherlands), anti-HLA-A,B,C mAb (W6/32; Seralab, 
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Sussex, U.K.), anti-CD3 (CLB-CD3), anti-CD2 (CLB-CD2), anti-CDSS (CLB-CD58), 
anti-CDlla/CDlS (CLB-CDlla), anti-CD54 (CLB-CD54; all from CLB, Amsterdam, 
The Netherlands), anti-CD4 (OKT4 culture supernatant), and anti-CDS (Bll6.Ll). 
G250 scFv/ygene transduction 
Activated T lymphocytes were transduced with the G250 scFv/y retroviral vector 
(L(scFv/yG250)SN) as descnbed (163). In short, activated T lymphocytes were 
cocultivated for 3 days with the irradiated L(scFv/yG250)SN-producing amphotropic 
packaging cell line PA317 in the presence of 360 IU/ml r!L-2 and 4 AAfml polybrene 
(Sigma Chemical Co., St. Louis, MO). Cocultivation was followed by 9 days G418 
selection and expansion in the presence of feeder cells as described previously (202, 
203). 
G250 Ag gene transfection 
Melanoma cell line lgR39 was electroporated with 10 I-'ll of G250 Ag eDNA in 
expression vector pCDMS (kindly provided by E. Oosterwijk, Nijmegen, the 
Netherlands) by using a BTX electroporator (BTX, San Diego, CA) at 250 V and a 
capacitance of 2000 !J}'. Three days after electroporation, the cells were used as target 
cells in the 51Cr release assay. 
Flow cytometry 
The expression of different surface molecules on effector and target cells was measured 
by direct and indirect immunofluorescence and flow cytometry on a FACScan flow 
cytometer (Becton Dickinson, Mountain View, CA). Cells were washed in phosphate 
buffered saline (PBS) containing 1 o/o bovine serum albumin (BSA) and resuspended in 
50 iJ] orPBS/1 o/oBSA. Fifty microliters of the diluted mAb was added and incubated for 
30 min at 4 oc_ Cells were washed once in PBS/1 o/oBSA, and for the indirect 
fluorescence, the second step annbody goat-anti-mouse phycoerythrin (PE)-conjugated 
was added for 30 min at 4 oc_ After incubations, cells were washed once in PBS/! o/oBSA, 
resuspended in lo/o paraformaldehyde containing 1 AAfml 7-AAD (Brunswig Chemie, 
Edison, NJ) and analyzed by flow cytometry. Incubation of cells with goat-anti-mouse 
PE-conjugated served as control staining. 
Cytotoxicity assay 
Cytotoxic activity was measured in a 4- or 5-h 51Cr-release assay. Briefly, varying 
numbers of effector cells were added in triplicate to 96-well microliter plates (100 
iJ]/well), followed by the addition of2500 target cells (100 IJ])/well. The target cells were 
labeled with 50 ~Ci 51Cr per 0,5xl06 cells for 2 h at 37 oc_ MAbs were added to the 
effector cells (CLB-CD2: 10 AAfml, CLB-CD3: 10 AAfml, OKT4: 1:4, Bll6.1: 10 AAfml, 
and CLB-CDlla: 10 AAfml) or to the target cells 0#6/32: 10 AAfml, CLB-CD58: 10 
AAfml, CLB-CD54: 10 AAfml and G250: 5 AAfml) 15-30 minutes before the addition of a 
fixed amount (n~2500) of 51Cr-labe!ed target cells. At the end of the 4-5-h incubation 
period (37 oc and 5% C02), supernatants were collected using a Skatron harvesting 
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system (Skatron, Lier, Norway) and counted in a gamma-counter (Wallac, Breda, The 
Netherlands). Percentage specific lysis was calculated as follows: ((test counts -
spontaneons counts) I (maximum counts- spontaneons counts)) x 100%. 
Conjugate formation assay 
Effector/target cell conjugate formation was assessed by FACS analysis (37). ScFv/y-
transduced CTL (5x106) were labeled with 0,075 )JM Calcein AM (green) 
(Calbiochem, San Diego, CA) in a volume of 5 ml at 37 'C for 60 min. Target cells 
(10x106) were labeled with 40 ~/ml hydroethidine (red) (Molecular Probe Inc., 
Eugene, OR) in a volume of 1 ml for 30 min at 37 'C. Effector and target cells were 
washed three times before use and diluted to 10x106 cells/mi. Twenty microliters of 
labeled target cells were mixed with an equal or 10-fold amount oflabeled effector 
cells with or without blocking mAb. MAbs were incubated with either effector or 
target cells for 30 min at 4 'C before conjugate formation. The final volume was 
adjnsted to 220 ~- Cell mixtures were centrifuged for 3 min in a serofuge and 
conjugates were allowed to form at 21 'C for 15 min. Conjugate assay was stopped 
by the addition of 500 ~ ice-cold PBS and kept on ice until analyzed on a F ACScan. 
Cells were resnspended on a vortex for 5 sec before analysis. Ten thousand target cell 
events were counted and the total number of events simultaneously emitting red and 
green fluorescence (conjugates) was divided by the total number of events emitting 
red fluorescence (target cells), yielding the percentage of target cells that had formed 
conjugates. 
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figure 3.1 Cytotoxicity of scFv/y~transduced CTL against RCC cell lines. ScFv/y~transduced CTL were 
incubated with renal carcinoma cell line A75 (A), SK-RC-17 cl.4 (B) and SK-RC-17 (C) and tested in a 4-
h 51Cr release assay. Blocking of cytolysis with G250 m.Ab was performed at a concentration of 5 ).!.g/ml. 
The specific 51Cr release is depicted at different Err ratios. (.) scG250-CTL; (o) scG250-CTL + G250 mAb. 
Experiments were performed in triplicate, and the SD did not exceed 10%. Similar results were obtained 
from at least two independent experiments. 
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RESULTS 
Cytolysis of RCC by scfvltredirected CTL 
To demonstrate redirection of human CTL specificity by molecular grafting with scFv/y 
receptor specific for RCC, cytolysis of different RCC cell lines was investigated. RCC 
A75 expressing G250 Ag was efficiently lysed by scFv/y-redirected CTL, and binding of 
parental G250 mAb to the target cells inhibited lysis (fig. 3.1A). No specific lysis was 
demonstrated against RCC target cell SK-RC-17 not expressing G250 Ag (Fig. 3.1C). 
Transfection of these G250 Aft" cell SK-RC-17 with the eDNA encoding G250 Ag 
resulted in membrane expression of G250 Ag and, consequently, these cells were 
specifically lysed by the scFv/y-redirected CTL (fig. 3.1B). This lysis was also inhibited by 
G250 parental mAb. 
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figure 3.2 Cell surface expression of adhesion and accessory molecules on scFv/y-redirected CTL and 
RCC. Adhesion and accessory molecules expression was determined by flow cytometry. (A) ScFv/f0 ' CTL 
were stained by indirect immunofluorescence with 2 J,lg/ml of the following antibodies: anti-CD2 ( CLB-
CD2), anti-CD3 (CLB-CD3), anti-CD4 (0KT4 culture supernatant), anti-CDS (Bll6.1.1) and anti-
CDlla!CDIS (CLB-CDlla), followed by incubation -with goat-anti-mouse PE-conjugated (GAM-PE). 
(B) RCC were stained by indirect immunofluorescence with 2 J.lg/ml of the following antibodies: G250 
mAb, anti-CD54 (CLB-CD54) and anti-CDSS (CLB-CDSS), followed by incubation with goat-anti-
mouse PE-conjugated (GA..\1-PE). Data are presented in histograms with relative cell number on they-
axis and relative fluorescence intensity (FL2) on the x-axis in log scale. For the RCC A75 and SK-RC-17 
cl.4 the mean fluorescence channel is indicated for each sample. 
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figure 3.3 Effect of mAb binding to scFv/y·transduced CTL on the scFv/y-mediated cytolytic activity 
against RCC A75 (A) and SK-RC-17 cl.4 (B). Percentage lysis in a 5-h 51Cr release assay of A75 was 
between 55% and 100% (EfT ratio from 20 to 60) and of SK-RC-17 d4 between 34% and 100% (E:T 
ratio from 20 to 60). The following mAb were used: anti-CD2 (CLB-CD2), 10 ).tg/ml; ariti-CD3 (CLB-
CD3), 10 J.Lg/ml; anti-CD4 (0KT4 culture supernatant), 1:4; anti-CDS (Bll6.1.1), 10 ).!.g/ml and anti-
CDlla/CDIS (CLB-CDlla), 10 ].lg/ml. Mean percentage inhibition of scFv/y-redirected cytolysis from the 
control is depicted with standard deviation (n>4). 
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figure 3.4 Effect of mA.b binding to the RCC on the cytolytic activity of scFv/y-transduced CTL against 
RCC A75 (A) and SK-RC-17 cl.4 (B). Percentage lysis in a 5-h 51Cr release assay of A75 was between 55% 
and 100% (E:T ratio from 20 to 60) and ofSK~RC~17 cl.4 between 34% and 100% (E:T ratio from 20 to 
60). The following mAb were used: anti-CD54 (CLB-CD54), 10 ~glml; anti-CDSS (CLB-CDSS), 10 ~g/ml 
and anti-HLA-A,B,C (W6/32), 10 ]lg/ml. Mean percentage inhibition of scFv/y-redirected cytolysis from 
the control is depicted with standard deviation (n>5). 
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Expression of adhesion and accessory molecules on 
scfv/"f"redirected CTL and RCC 
The expression of adhesion and accessory molecules on scFv/y-redirected CU and RCC 
was analyzed by flow cytometry. All cells in the scFv/y-transduced bulk population were 
positively stained with antibodies against CD2, CD3, CDS and CD11a/CD1S (fig. 3.2A). 
The RCC A75 and SK-RC-17 cl.4 stained positive with anti-CD54 mAb, anti-CDSS 
mAb and G250 mAb (fig. 3.2B). RCCA75 showed a higher level ofG250 Ag, CD54 and 
CDSS expression compared to SK-RC-17 cl.4. 
• ~
ro 
• ~ 
~ 
"" 
100 
80 
60 
40 
20 
0 
0,02 0,08 0,3 1,2 5 
J.Jg/ml G250 mAb 
•G250 
~G250+C054 
figure 3.5 Binding of G250 mAb to the G250 Ag resulted in anti-CD54 mAb sensitive scFv/y-redirected 
lysis ofRCC A75. RCC A75 target cells were incubated with or without different concentration of G250 
mAb (solid bars) and G250 mAb + anti·CD54 mAb (hatched bars). Cytolysis of RCC by scFv!'f'"' CTL 
was measured in a 5-h 51 Cr release assay. Blocking of cytolysis with G250 mAb was performed at the 
indicated concentrations and blocking with anti-CD54 mAb at 10 J.lg/ml. The specific 51 Cr release is 
depicted at an E:T of 60. Experiments were performed in triplicate, and the SD did not exceed 10%. 
Similar results were obtained from two independent experiments. 
Addition of anti-CD2, -CD3 and -CD11a/CD18 mAbs to the CTL inhibits 
scfV/"f"redirected tumor cell lysis 
To investigate whether the newly expressed scFv/y chimeric receptor could functionally 
interact vvith adhesion and accessory molecules like the endogenous TCR, we 
performed studies in which lysis of the RCC A75 and SK-RC-17 cl.4 was performed in 
the presence of soluble mAbs against CD2, CD3, CD4, CDS and CDlla/CD1S. As 
shown in fig. 3.3A,B, binding of soluble mAb to CDS, which is involved in binding and 
signaltransduction of MHC class !-restricted cytolysis, expectedly had no effect on the 
level of cytolysis, demonstrating the anticipated lack of MHC restriction of scFv/y-Ag 
interaction. Anti-CD4 mAb served as negative control in this experiment, since no 
CD4-positive T cells were present in the culture. The importance of CD2 and 
CDlla/CDlS adhesion molecules in T cell-mediated RCC lysis was clearly 
demonstrated by the fact that target cell lysis was indeed inhibited by the relevant mAbs. 
Interestingly, binding of anti-CD3 mAb to the scFv/f"" CTL/target cell mixture resulted 
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in a significant (57%) inhibition of cytolysis of both A75 and SK-RC-17 cl.4 RCC cells 
(fig. 3.3A,B). Effector/target cell conjugate formation was not affected by addition of.. 
these mAbs, suggesting that the inhibition of cytolysis represents the delivery of a 
negative signal to the CTL which blocked triggering of the cytolytic machinery of the 
scFv/yreceptor following G250 Ag recognition (data not shown). 
lgR39 
lgR39 G250Ag 
lgR39 G250Ag 
+TNFa 
figure 3.6 Cell surface expression of adhesion molecules on melanoma IgR39 and G250 Ag~transfected 
melanoma IgR39·G250Ag. Adhesion molecules expression was determined by flow cytometry. To induce 
CD54 expression, IgR39 cells were cultured in the presence of 1000 U/ml recTNFa for 24 h. Cells were 
stained by indirect immunofluorescence with 2 ).l.g/ml of the following antibodies: anti-CD54 (CLB-
CD54) and G250 mAb, followed by incubation with goat-anti-mouse PE-conjugated (GAM-PE). Data are 
presented in histograms with relative cell number on they-axis and relative fluorescence intensity (FL2) 
on the x-a.'ris in log scale. 
Addition of anti-CD58 and -CD 54 to the target cell inhibits scfv/y-
redirected tumor cell cytolysis, but the level of inhibition 
depends on the expression level of G250 Ag 
Whereas addition of anti-CD58 and anti-HLA-A,B,C to the RCC target cells did not 
affect cytolysis, anti-CD54 did inhibit cytolysis of RCC SK-RC-17 cl.4 but not of the 
RCC A75 (fig. 3.4A,B). This differential effect may be due to quantitative differences in 
tumor cell surface G250 Ag and CD54 expression. Indeed, RCC A75 was found to 
express high levels ofG250 Ag and CD54, whereas RCC SK-RC-17 cl.4 cells exhibited 
intermediate levels of G250 Ag and CD 54 expression. Even the addition of 25 !J,giml of 
anti-CD54 mAb did not inhibit scFv/y-redirected cytolysis of RCC A75 (data not 
shown). This functional correlation between G250 Ag density and susceptibility to lysis 
was further supported by our finding that, when the levels of free G250 Ag molecules 
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on RCC A75 by addition of non-saturating concentrations of G250 mAb were 
decreased, the lysis of RCC A75 became susceptible to inlubition by anti-CD54 mAb 
(fig. 3.5). Binding of 0,3 !lgiml G250 mAb to RCC A75 resulted in a 50 % decrease in 
the number of free G250 Ag molecules on RCC A75 as analyzed by FACS with G250 
mAb and goat-anti-mouse Ig PE-conjugated (data not shown) and hence A75 now 
expressed levels of free G250 Ag molecules similar to those expressed by SK-RC-17 cl.4. 
Binding of anti-CD54 and anti-CD58 mAb to RCC SK-RC-17 cl.4 cells did not affect 
the percentage of effector/target cell conjugates formed (data not shown). 
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figure 3.7 Cytotoxicity of scFv/y-transduced en against G250 Ag positive and negative melanoma cell 
lines. ScFvfr-transduced CfL were incubated with (A) melanoma IgR39 (G250 Agnog), (B) TNFo:-treated 
lgR39 (G250 Ag"~), (C) lgR39·G250Ag (G250 Ag''") and (D) TNFa·treated lgR39-G250Ag (G250 Ag"") 
and tested in a 4-h 51Cr release assay. For blocking of cytolysis the following mAb were used: anti-CD54 
(CLB-CD54; 10 ).lg/ml) and G250 mAb (5 ).lg/ml). The specific 51 Cr release is depicted at different E:T 
ratios. (•) scG250-CTL; (o) scG250-CTL + G250 mAb; (A) scG250-CTL + CD54 rnAb. Experiments were 
performed in triplicate, and the SD did not exceed I Oo/o. 
Cytolysis of G250 Ag""' melanoma cell line by scFv/')"redirected CTL 
To further investigate the coregulation of scFv/y-mediated CTL cytolysis of target cells, 
we transfected the G250 Ag gene into melanoma cells which showed no detectable levels 
of CD54 on the membrane. Transfection of melanoma IgR39 with G250 Ag eDNA 
resulted in a large percentage (>60%) of cells expressing high levels of G250 Ag (fig. 
3.6). At least 25% of the transfected IgR39 showed a G250 Ag expression level that was 
as high as the dense G250 Ag expression on A75. As expected, parental melanoma 
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lgR39 cells were not lysed by scFv/y-redirected CTL, but G250 Af,''" cells were readily 
lysed by scFvly-redirected CTL even in the absence of detectable CD54 (fig. 3.7A,C). 
This lysis could not be inhibited by the addition of anti-CD54 mAb to the scFv/1"" 
CTL/target cell mixture, excluding a role for undetectable low levels of CD 54. Addition 
of tumor necrosis factor a. (TNFa.) resulted in readily detectable levels of CD54 (fig. 3.6) 
and, subsequently, the level of scFv/y-mediated lysis of the G250 Ag"''-CD54''" 
melanoma cells also increased (fig. 3.7D). To exclude that the induced expression of 
unknown tumor cell membrane molecules by TNFa. was responsible for the increased 
level of scFv/y-mediated cytolysis, we added anti-CD54 mAb. The level of cytotoxicity 
again decreased (fig. 3.7D). The specificity of the interaction was demonstrated by 
inhibition of scFv/y-mediated lysis with parental G250 mAb (fig. 3.7C,D). 
DISCUSSION 
Adhesion and accessory molecules play critical roles in cell-cell interactions in general 
and in TCR/Ag interactions in particular (35). Here, we identified functional 
interactions in the cytolytic process of CD2, CD3 and CDlla/CD18 with the chimeric 
receptor scFv/y. Moreover, we demonstrated the requiretnent for CDlla!CD18-CD54 
interaction between T cell and target cell in case the expression level of (free) G250 TAA 
becomes limiting. 
Binding of mAbs to T lymphocyte CD2, CD3 or CDlla/CD18 molecules can either 
enhance or inhibit T cell functions such as activation, conjugate formation with target 
cells and/or cytolysis (20, 197, 204, 205). Cross-linking of signaling molecules by mAbs 
or multimeric ligands that bind to accessory molecules induce T lymphocyte activation, 
whereas the addition of soluble mAbs to these molecules delivers a negative signal to 
cells (33). For CD2, CD3 or CD!la/CD18 molecules, both stimulatory and inhibitory 
signaltransducing properties have been described in normal MHC-restricted TCR/Ag 
interactions (35), NK cells (36) and bsmAb-mediated interaction (37, 198, 199). A 
similar involvement of CDlla!CD18 in regulation was demonstrated for chimeric 
Ig/TCR-mediated cytolysis of target cells when Ag was recognized with low avidity 
(206). We wanted to determine whether the coregulatory signaling pathways of CD2, 
CD3 and CDlla/CD18 were also functionally related to the artificially induced tumor-
specific scFv/y receptor expressed on human T lymphocytes. Binding of mAbs to CD2, 
CD3 and CD11a/CD18 molecules on scFv/f"' human CTL inhibited cytolysis. Because 
these antibodies did not inhibit the effector/target cell conjugate formation, we suggest 
that inhibition of lysis was due to the delivery of an inhibitory signal to the CTL 
cytoplasm via these coactivation molecules. 
At the target cell level no inhibition of conjugate formation or cytolysis occurred 
following binding of anti-CD58 mAb, indicating that the CTL/target cell CD2-CD58 
interactions are not limiting in scFv/y-redirected lysis. Apparently, the inhibitory effect 
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of anti-CD2 binding is not the result of interference with the CD2-CD58 interaction, 
but rather the delivery of a negative signal to the T lymphocyte following binding of 
soluble anti-CD2 to CD2 molecules. Binding of anti-CD54 mAb to RCC target cells 
expressing intermediate levels ofCD54 and G250 Ag (SK-RC-17 cl.4) inhibits cytolysis, 
demonstrating the importance of CD11a/CD18-CD54 interaction in scFv/y-mediated 
lysis. Effector/target cell conjugate formation was not inhibited by anti-CD54 mAb, 
suggesting that inhibition of cytolysis was due to interference with the CD11a/CD18-
CD54 coactivation signal. Since no inhibition of cytolysis was observed on RCC target 
cells expressing high levels of both CD54 and G250 Ag (A75), even after binding of an 
equal or even higher concentration of mAb to CD54, it could be argued that the 
absence of inhibition by anti-CD54 in cytolysis of high CD54/high G250 Ag expressing 
cells was due to the involvement of other ligands for CD11a/CD18, sucb as CDSO and 
CD102. However, a 50% reduction of free Ag on the RCC A75 by addition of parental 
G250 mAb to the target cells mllnics the 'intermediate' G250 Ag expression level as seen 
for RCC SK-RC-17 cl.4 and at the same time rendered them sensitive to anti-CD54 
mAb inhibition of cytolysis. Hence CD!la/CDI8-CD54 adhesion interactions are 
critical in scFv/y-mediated lysis but only when the number of Ag on the target cell 
becomes limiting. High levels of G250 Ag on the target cells bypass the requirement for 
additional CD11a/CD18-CD54 interaction. We previously demonstrated this to be the 
case for induction of bsmAb-mediated lysis of melanoma cells IgR39, i.e., high 
concentration of bsmAb could induced lysis of tumor cells without or with only a 
FACS-undetectable level ofCD54 expression (37). This conclusion is further supported 
by our finding that lysis of G250 Ag gene-transduced, melanoma cell line lgR39 
occurred, engineered to express intermediate and high levels of G250 Ag, and low or no 
CD 54 expression. Upregnlation of CD 54 expression after TNFa treatment resulted in 
an increase in the level of scFv/y-mediated cytolysis, most likely because also the 
intermediate G250 Ag-expressing melanoma cells become lysed. Although additional 
coregnlatory molecules and their ligands may play a role in the lytic CTL/target cell 
interactions, our results demonstrate the critical involvement of CD2, CD3 and 
CD!la/CD18, and for CD11a/CD18-CD54 interaction its requirement becomes 
apparent at limiting tumor Ag concentrations. 
We earlier showed that scFv/f'" CTL produce cytokine upon RCC interaction, 
specifically lyse RCC and recycle their lytic capacity (163). Here, we demonstrate 
that this genetically introduced scFv/y receptor is functionally coregnlated by CD2, 
CD3 and CD11a/CD18 molecules, as described for endogenous NK receptor, a~ and 
yo receptors (16, 20, 35, 36, 207). Because the soluble mAb do not affect effector cell-
target cell conjugate formation, we conclude that the inhibition ofT cell-mediated 
cytolysis is due to interference with coregulatory signaling. Hence, the y-cbain in the 
chimeric receptor performs signaltransducing functions that can be coregnlated 
intracellularly via the CD2, CD3 and CD11a/CD18 signaling pathways. Moreover, 
CTL/target cell CD11a/CD18-CD54 interactions were required only when the RCC 
expressed low or intermediate levels of G250 Ag but not at high Ag density. For 
immunotherapy of cancer this may prove an important advantage, since tumor cell 
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variants express no or low levels of CD 54 (208). Furthermore, in patients with RCC 
metastases, soluble CD54, which may circulate in body fluids (208, 209), might .. 
otherwise inhibit normal cell-cell interaction and hence cytolysis (210, 211). 
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SUMMARY 
Genetic engineering ofT lymphocytes for adoptive clinical immunotherapy calls for 
efficient gene transduction methods. Therefore, a transient retroviral gene 
transduction system 'STITCH' ;vas developed comprising pSTITCH retroviral vector 
encoding the transgene, plasmids encoding Moloney murine leukemia virus gag/pol 
and gibbon ape leukemia virus envelope, and the human kidney cell line 293T as a 
packaging line. Co-transfection of retroviral vector and packaging plasmids in 293T 
cells results in the production of GAL V env pseudotyped viral particles with a titer of 
107 infectious units/mi. The 'STITCH' gene transduction system efficiently 
transduces genes into activated human T lymphocytes derived from healthy donors 
and cancer patients. The efficacy of gene transduction is donor-independent. A 
direct application of 'STITCH' gene transduction system is the genetic engineering 
of activated human T lymphocytes to induce expression of antibody based chimeric 
receptors in their membrane. Introduction of these chimeric receptors into activated 
human T lymphocytes graft these cells with specificity for, for example, renal cell 
carcinoma. In order to study the effect of the chimeric receptor gene structure on 
the processes ultimately leading to functional membrane expression, we designed a 
number of different chimeric receptor gene structures and subsequently compared 
their membrane expression on 293T cells and activated human T lymphocytes. 
Distinct membrane eA-pression densities were observed on 293T cells and human 
T lymphocytes for the different chimeric receptor gene constructs. Gene transduc-
tion of activated human T lymphocytes with 4 out of 5 chimeric receptor gene 
constructs resulted in functional eA-pression of chimeric receptor as demonstrated by 
specific recognition and cytolysis of renal cell carcinoma. 
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INTRODUCTION 
T lymphocytes are useful as therapeutic agents in viral diseases (212, 213), and 
cancer (132, 214, 215). Genetic manipulation ofT lymphocytes may improve their 
efficacy in adoptive immunotherapy, e.g. by the introduction of cytokine encoding 
genes in tumor infiltrating T lymphocytes (216), introduction of the adenosine 
deaminase (ADA) gene into Tlymphocytes from SCID patients (189, 217), 
expression of chimeric receptors on the membrane of T lymphocytes to endow 
tumor specificity ( 155), or the transfer of suicide genes into donor T lymphocytes to 
control for allogeneic graft-versus-leukemia (218). Up till now, retroviral gene 
transduction has been the most efficient and safe method for stable introduction of 
genes into cells (219). The retroviral vector LXSN and derivatives (186) are 
widespread used vectors for clinical application. 
We have successfully engineered anti-CD3 activated human T lymphocytes with 
antigen receptors genes to redirect T lymphocytes to renal carcinoma cells (RCC) 
(163). These chimeric antigen receptor genes comprise the binding site of a RCC 
specific mAb, G250, and the signaltransducing y-chain molecule ofFc(e)RI. We have 
shown that these chimeric receptor transduced activated human T lymphocytes can 
specifically recognize and lyse RCC target cells via the transduced chimeric Ig 
receptor (scFvG250) and produce cytokines following specific target cell interaction. 
However, the gene transduction efficiency obtained with the LXSN vector is low and 
requires repeated, laborious selection procedures. Moreover, although functional 
expression of the chimeric receptor is observed, the membrane expression levels are 
so low that it can not be detected by flow cytometry. A higher expression level of the 
chimeric receptor would (a) allow rapid screening and immunoselection of 
scFvG250 positive T lymphocytes, (b) facilitate receptor structure-function analysis, 
(c) allow monitoring of trafficking and half-life of the gene transduced 
T lymphocytes following adoptive in vivo transfer to patients and overall quality 
control assessment; and (d) possibly prolong cytolytic capacity of the T lymphocyte. 
In the last few years transient gene transduction systems have been reported that 
resulted in high titer production of retroviral vector particles, but these are either 
not readily available for clinical use, or not optimized for gene transduction of 
human T lymphocytes (220-223). Therefore we set out to construct a retroviral gene 
transduction system with high gene transduction efficiency and functional gene 
expression in activated human T lymphocytes. The 'STITCH' transient gene 
transduction system we developed consists of: (a) the retroviral vector pSTITCH 
encoding the transgene; (b) the plasmids pHIT60 (222) and pCOLT-GALV 
encoding Moloney murine leukemia virus gag/pol and gibbon ape leukemia virus 
envelope, respectively; and (c) the human kidney cell line 293T as the packaging cell 
line. Cotransfection of all three constructs into 293T cells resulted in high titer 
production of GAL V pseudotyped viral particles, which had earlier been shown to 
infect a wide range of cell types, including human T and B cells (224, 225). In 
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addition to efficient introduction of the scFvG250 chimeric gene into the activated 
human T lymphocytes, functional expression of chimeric single chain receptor 
requires passage through the quality control mechanism of the endoplasmic 
reticulum and proper protein folding, transportation to the membrane and linkage 
to the intracellular signaling pathways. In order to study the relation between gene 
structure and functional membrane expression) we designed 7 different chimeric 
receptor gene constructs that vary in: (a) the configuration of the variable heavy and 
variable light chain sequences; (b) the hinge domain sequence; and (c) the sequence 
of the transmembrane domain and signaltransducing cytoplasmic tail, and tested 
expression in 293T cells and activated human T lymphocytes using the 'STITCH' 
gene transduction system. 
Here, we present the development of the 'STITCH' gene transduction system. We 
show that activated human T lymphocytes of multiple donors are efficiently 
transduced using the 'STITCH' system within 1 week. An increase in membrane 
expression of the scFvG250 chimeric receptor construct is observed using pSTITCH 
retroviral vector in comparison with LXSN vector. Different scFvG250 chimeric 
receptor gene constructs are functionally expressed in activated human 
T lymphocytes and their membrane expression levels are dependent on the 
structures of the scFv chimeric receptor gene dictating the protein three-
dimensional structure. 
MATERIALS AND METHODS 
Cells and antibodies 
293T cells (kindly provided by Dr. Y. Soneoka, Oxford, UK) and CF2TH cells 
(ATCC, CRL-1430) were cultured in DMEM medium (BioWhittaker, Verviers, 
Belgium) containing 10% BCS (HyClone Laboratories, Inc. Logan, UT), 100 U/ml 
penicillin and 100 )lg/ml streptomycin. PEL of healthy donors were isolated by 
centrifugation through Lymphoprep (d=1,077 gicm') (Nycomed Pharma, Oslo, 
Norway) and activated in Mix-med culture medium (78% RPM! 1640 buffered with 
bicarbonate (2 gil) and HEPES (25 mM) (Bio Whittaker, Verviers, Belgium), 20% 
AIM-V (Life Technologies, Grand Island, NY), 2% heat inactivated human serum, 2 
mM glutamine, 100 U/ml penicillin and 100 !lg/ml streptomycin; (8)) with 10 ngiml 
OKT3 ( Ortho Diagnostic System, Beerse, Belgium) at a density of 0.5x1 06 cells/ml. 
After 3 days of activation, lymphocytes were washed and cultured in RPM! culture 
medium (RPM! 1640 buffered with bicarbonate (2 gil) and HEPES (25 mM), 10% 
heat inactivated human serum, 2 mM glutamine, 100 U/ml penicillin and 100 !lg/ml 
streptomycin) supplemented with 360 !U/ml human recombinant IL-2 (r!L-2) 
(Chiron, Amsterdam, The Netherlands). The following cell lines were used as targets 
in cytotoxicity assays: SK-RC-17 Cl.l (mock-transfected RCC cell line) and SK-RC-
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17 Cl.4 (G250 Ag cDNA-transfected RCC cell line)(kindly provided by Dr. E. 
Oosterwijk, Nijmegen, The Netherlands). The antibodies used for staining the cells 
were: anti-idiotype mAb NUH-31 and NUH-82 (Dr. E. Oosterwijk) and anti-CD24 
(CLB-CD24; CLB, Amsterdam, The Netherlands). 
STITCH gene transduction system 
The basis of pSTITCH retroviral vector is SFG (kindly provided by Dr. L Riviere) a 
derivative ofMFG (64) which contains 5 mutations at the 5' of the gag sequence. To 
construct the pSTITCH vector the U3 region of the 5' LTR of SFG was replaced by 
the human CMV IE promoter/enhancer (isolated from PHIT110, kindly provided by 
Y.Soneoka) and the plasmid backbone contains the SV40 ori. 
All construct were all introduced into pSTITCH by using 5' Nco! site and 3' BamHI 
site. The HKy construct was made as described (163) and a Nco! site was introduced 
at the startcodon by using PCR. The CD4 transmembrane region sequence 
(nucleotides 1258-1329; (226)) and CD3 !;-chain sequence (nucleotides 228-568; 
(185)) were derived from mRNA of human PBL and human CTL clone D11, 
respectively, by reverse transcriptase followed by PCR. Short G250 joining gene 
region (J) contained only the first 3 of 11 a.a. of G250 JK and the first 3 of14 a.a. of 
G250 JH- Hinge-CH2-CH3 region DNA (aminoacid 11 of the hinge domain to 107 
of the CH3; (227)) was amplified by PCR from a plasmid containing genomic IgG1 
DNA (kindly provided by Dr. E. Timmers). To generate the kappa-heavy (KH) 
configuration, the same strategy as for HK y construct was followed. The coding 
sequence of CD24 was generated by PCR using PUCI9-CD24 (kindly provided by 
Dr. K. Humphries, Vancouver, Canada) introducing a Nco! site at the transcription 
startcodon and a BamHI site after the stopcodon. LacZ sequence was isolated from 
pSV -~-galactosidase (Pro mega Corporation, Madison, WI) by PCR. For cloning into 
pSTITCH, a Nco! site was introduced at the startcodon and a stopcodon and BamHI 
site was introduced at position 3754. For the transient packaging system the 
following plasmids are used: pHIT60, a LXSN based vector containing the gag-pol 
genes of MLV retrovirus, pHIT456, a LXSN based vector containing the MoMLV 
envelope gene, both containing the CMV IE promoter/enhancer and SV40 ori (both 
kindly provided by Dr. Y.Soneoka, London UK; (222)), pCOLT-GALV a vector 
containing GAL V env gene, CMV IE promoter/enhancer, ~-globulin intron II and 
SV40 ori. 
Transfection and gene transduction methods 
Transient transfections were performed in 293T cells by using a CaPO, transfection 
kit (Life Technologies). 293T cells (2xl06) were seeded in 10-mm dishes and 24 h 
later CaPO,-transfected with 20 AA of the pSTITCH vector. Transfected cells were 
cultured for another 24 h after which the transfection medium was replaced by 10 
ml of fresh medium. The following day, cells were analyzed by FACS for membrane 
expression of the inserted gene. For stable gene transduction, retroviral particles 
were generated after transfection of 293T cells with 20 AA of pHIT60, pCOLT -GAL V 
60 
- -- / 
and pSTITCH retroviral vector by using CaP04 transfection. Twenty-four !lours 
after transfection, cells were irradiated (25 Gy) and co-cultured for 3 days with 
0,5xl06 anti-CD3 activated PBL/ml. Cocultivation was performed in RPM! culture 
medium (RPM! !640 buffered with bicarbonate (2 gil) and HEPES (25 mM), !Oo/o 
heat inactivated human serum, 2 mM glutamine, 100 U/ml penicillin and 100 ~g/ml 
streptomycin) supplemented with 360 IU/ml human recombinant IL-2 (riL-2) and 4 
~ml polybrene (Sigma Chemical Co., St. Louis, MO). 
Determination of viral titer 
For determination of the virus titer, retroviral particles were generated after 
transfection of293T cells with 20 ~g ofpHIT60, pCOLT-GALV and pSTITCH-lacZ 
retroviral vector by using CaP04 transfection. Twenty-four hours after transfection, 
medium was replaced by 5 ml of fresh medium. Retroviral supernatant was harvest 
after 24 h and filtered through a 0,45 ~ filter (Millipore S.A., Molsheim, France) 
and diluted in medium. CF2TH cells (2xl04 ) were seeded in 6-wells culture plates 
and 24 h later medium was replaced by viral supernatant dilutions supplemented 
with 8 ~ml polybrene. After 4 days the percentage of positive colonies was counted 
after staining with X-gal (228). 
lmmunomagnetic purification of scFvG2SO""' T lymphocytes 
scFvG250'0 ' T lymphocytes were purified by using immunomagnetic isolation with 
NUH-31 mAb. T lymphocytes (5xl06) were incubated with 10 fl.) NUH-31 mAb (2 
~g/ml) for 30 min at 4 oc_ After incubation cells were washed twice and resuspended 
in 250 fl.) of culture medium. Magnetic particles (25 fl.)) (Magnisort, Dupont, 
Wilmington, DE) were washed twice and also resuspended in 250 fl.) culture 
medium. Magnetic particles were added to the cells and incubated on a rollerbank 
for 30 min at 4 oc_ Following incubation, 9,5 ml medium was added and cells were 
selected against a magnet (Dynal, Oslo, Norway) for 10 min. Medium was replaced 
by fresh medium and magnet incubation was repeated. Medium from step 1 and 2 
was pooled and another 10 min incubation against the magnet was performed. Cells 
containing the magnetic particles were cultured and 4 days later analyzed on FACS 
with anti-idiotype mAb NUH-82 and goat-anti-mouse Ig PE-conjugated for 
expression of the chimeric receptor. 
Flow cytometry 
The membrane expression of different molecules on 293T cells and T lymphocytes 
was measured by direct and indirect immunofluorescence and flow cytometry on a 
FACScan flow cytometer (Becton Dickinson, Mountain View, CA). Cells were 
washed in PBS containing 1 o/o BSA (PBS/BSA) and resuspended in 50 fl.) of 
PBS/! o/oBSA. Fifty microliter of the diluted mAb was added and incubated for 30 
min at 4 oc_ Cells were washed once in PBS/! o/oBSA and for the indirect fluorescence 
the second step antibody goat-anti-mouse Ig PE-conjugated was added for 30 min at 
4 oc_ After incubations cells were washed once in PBS/ 1 o/oBSA, resuspended in 1 o/o 
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paraformaldehyde containing I AAfml 7-AAD (Brunswig Chemie, Edison, NJ) and 
analyzed by flow cytometry. Treatment with goat-anti-mouse Ig PE-conjugated 
served as control staining. 
Cytotoxicity assay 
Cytotoxic activity was measured in a 4-h 51 Cr-release assay. Briefly, varying numbers 
of effector cells were added in triplicate to 96-well microliter plates (100 fJ]Jwell), 
followed by the addition of 2500 target cells (100 !J.])/well. The target cells were 
labeled with 50 ~Ci 51Cr per 0,5x!06 cells for 2 h at 37 oc. At the end of the 4-h 
incubation period (37 oc and 5% C02), supernatants were collected by using a 
Skatron harvesting system (Skatron, Lier, Norway) and counted in a gamma-
counter (Wallac, Breda, The Netherlands). Percentage specific lysis was calculated as 
follows: ((test counts - spontaneous counts) I (maximum counts - spontaneous 
counts)) x 100%. 
RESULTS 
STITCH transient gene transduction system 
The 'STITCH' transient gene transduction system comprises: (a) pSTITCH 
retrovira! vector; (b) plasmids pHIT60 and pCOLT-GALV; and (c) 293T packaging 
cells. Because clinical application of gene-transduced activated human 
T lymphocytes requires high gene transduction efficiencies, it was developed to 
produce high titer of recombinant pseudotyped retroviral vectors in less then one 
week. pSTITCH retrovira! vector contains splice donor/splice acceptor sides and the 
5' retroviral gag sequence for stable encapsidation and better transcription and 
packaging of the transgene as described for the MFG retroviral vector (64). In 
addition, pSTITCH was constructed to contain both the human CMV IE 
promoter/enhancer and the SV40 ori to further increase the viral titer (fig. 4.1). In 
combination with the use of the 293T packaging cell line this was expected to result 
in high level of expression of the transgene because: (a) constructs containing the 
human CMV IE promoter/enhancer will be activated by adenovirus early proteins 
that are present in 293T cells (229); and (b) 293T cells express the SV40 large T 
antigen which increases the copy number of constructs containing the SV 40 ori 
(222, 230). However, high level of retrovira! particles production not ouly requires 
efficient expression of the transgene but also of the packaging plasmids. Therefore, 
the packaging plasmids pHIT60 and pCOLT -GALV also contain the human CMV 
IE promoter/enhancer and the SV40 ori (fig. 4.1). Indeed high titers of retroviral 
particles (107 infectious units/ml) were obtained by using the pSTITCH vector and 
293T packaging cells. This was demonstrated after transfection of pSTITCH-lacZ 
vector and packaging plasmids in 293T cells and subsequent titration of the obtained 
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GALVenv poly A SV40 ori 
figure 4.1 Retroviral vector and envelope construct. (A) pSTITCH retroviral vector: U3 region of the 5' 
long terminal repeat (LTR) has been replaced by the human CMV IE promoter/enhancer. Also included 
in the vector are the extended Moloney Murine Leukemia Virus (MoMuL V) packaging signal ('¥) splice 
donor and splice acceptor sides (SD, SA), a cloning site at the envelope gene position, and the 3' 
MoMuLV LTR. The viral sequences are cloned in an SV40 ori containing plasmid, (B) Gibbon ape 
Leukemia Virus (GaLV) envelope gene cloned in e.'q>ression plasmid pCOLT containing the CMV 
promoter/enhancer, ~-globulin intron sequence and SV40 ori. 
retroviral particles on CF2TH cells and counting of the gene-transduced cells after 
X-gal staining (data not shown). 
Use of GALV envelope pseudotyped virus particles for gene 
transduction of activated human T lymphocytes results in higher 
gene transduction efficiency 
To determine the gene transduction efficiency of MoML V and GAL V env 
pseudotyped retroviral particles on the one hand and to investigate whether the 
efficiencies are donor-dependent on the other, we set out to transduce activated 
human T lymphocytes derived from 6 healthy donors with either GAL V env 
pseudotyped or MoMLV retroviral particles. CD24 was used as a marker gene to 
determine the percentage of gene-transduced T lymphocytes because CD24 can be 
expressed on the membrane of T lymphocytes and easily be detected by flow 
cytometry (231). Gene transduction of activated human T lymphocytes was 
accomplished after cocultivation of anti-CD3 activated PEL with irradiated 293T 
packaging cells producing pSTITCH-CD24 retroviral virus particles by using either 
GAL V env or MoMLV env. The percentage of CD24po' T lymphocytes was 
determined by FACS with anti-CD24 Ig FITC conjugated. FACS analysis showed 
that the percentage of CD24'0 ' T lymphocytes from all donors was higher after gene 
transduction using retroviral particles with GAL V env (20%) than with MoMLV env 
(8%) (table 4.1). It had to be excluded that the observed differences in gene 
transduction efficiency in T lymphocytes with GAL V env pseudotyped and MoML V 
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retroviral vector particles were due to differences in viral titers. Hence, the infection 
of retroviral vector particles on CF2TH cells was determined because these cells are 
susceptible to gene transduction by GAL V as well as MoMLV viruses. Infection of 
CF2TH cells showed an even better gene transduction efficiency with MoML V env 
retroviral particles than with GAL V pseudotyped retroviral particles (data not 
shown). 
table 4.1 Increased gene transduction efficiency in activated human T lymphocytes derived from 6 healthy 
donors with GAL V env pseudo typed retroviral vectors 
Donor 
MoMLVenv 
GALVenv 
10 
26 
2 
8 
21 
3 4 
% CD24po> T lymphocytesJ 
8 8 
22 21 
5 
7 
17 
6 
6 
20 
"Activated human T lymphocytes were gene transduced by cocultivation 'IIIith 293T cells producing either 
CD24 MoMLV env or GAL V env pseudotyped retroviral vectors. Three days after gene transduction the 
percentage of CD24f'O' T lymphocytes -was determined by F ACS with anti-CD24 Ig FITC-conjugated. 
Percentage CD241"'' T lymphocytes above background staining is presented. 
Increased membrane expression of scfvG250 chimeric receptor on 
activated human T lymphocytes following gene transfer with pSTITCH 
versus LXSN retroviral vector 
The 'STITCH' gene transduction system has been developed to result in both high 
gene transduction efficiency and functional gene expression in activated human 
T lymphocytes. A high gene transduction efficiency of activated human 
T lymphocytes using pSTITCH retroviral vector with GAL V env pseudotyped virus 
particles versus ML V env retroviral particles has been demonstrated. We also 
compared scFvG250 chimeric receptor gene expression in retroviral vector 
pSTITCH versus LXSN. Construct 'A', which contains the variable heavy chain 
linked to the variable kappa chain gene sequence of the mAb G250 and the y-chain 
of the Fc(e)RJ (fig. 4.2A), was used previously for gene transduction of activated 
human T lymphocytes. Activated human T lymphocytes were transduced with gene 
construct 'A' in LXSN retroviral vector and showed functional expression of the 
scFvG250 chimeric receptor, but the level of membrane eA'Pression could not be 
detected by flow cytometry even after G418 selection of the gene-transduced 
T lymphocytes (163). Transduction of activated human T lymphocytes derived from 
the same donor with construct <A' in pSTITCH retroviral vector, however, resulted 
in a membrane expression of the chimeric receptor on the T lymphocytes as 
determined by flow cytometry after staining with anti-idiotype mAb (NUH-82) and 
goat-anti-mouse PE-conjugated (fig. 4.4A). 
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figure 4.2 Single chain G250 chimeric receptor constructs. Single chain G250 constructs comprising the 
G250 rnAb V-heavyN-kappa (A-D) or the V-kappa!V-heavy (E-G) configuration have been coupled to 
(A) the complete joining gene segment (J,;:), CKS and the signaltransducing Fc(e)RI y-chain; (B) JK, CKS> 
CD4 transmembrane region and signaltransdudng cytoplasmic y-chain part; (C) short joining gene 
segment coupled to Ig hinge region and CH2CH3 regions, CD4 transmembrane region and 
signaltransducing cytoplasmic ;;-chain part from the TCR/CD3 complex; (D) complete joining region 
coupled to Ig hinge region and CH2CH3 regions, CD4 transmembrane region and signaltransducing 
cytoplasmic ;;-chain part; (E) the complete joining gene segment (JH), CH;;, CD4 transmembrane region 
and signaltransducing cytoplasmic y-chain part; (F) short joining gene segment (JH) coupled to Ig hinge 
region and CH2CH3 regions, CD4 transmembrane region and signal transducing cytoplasmic S -chain part 
from the TCR/CD3 complex; (G) complete joining region (JH) coupled to Ig hinge region and CH2CH3 
regions, CD4 transmembrane region and signaltransducing cytoplasmic S -chain part. 
Construction of scFvG250 chimeric receptor genes 
To optumze membrane expression which allows immunoselection of receptor 
expressing T lymphocytes, structure-function analysis and monitoring of gene-
transduced T lymphocytes following adoptive in vivo transfer, 7 different scFvG250 
genes were constructed (fig. 4.2). Replacement of the transmembrane region of the 
y-chain by the transmembrane CD4 region in construct 'B' removes the dimeri7.ation 
signal present in construct 'A'. This will result in expression of the scFvG250 as a 
monomeric molecule (fig. 4.2B). It has been described that a spacer segment 
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inserted between tbe scFv and tbe signaltransducing 1;-cbain is a structural 
prerequisite for antigen binding (232). Constructs 'A' and 'B' contain only a srnall 
spacer region (15 a.a.), comprising a part of tbe constant kappa chain and an 
extracellnlar !;-gene sequence, located between tbe scFvG250 and tbe 
transmembrane region. Thus, constructs cc' and 'D' were generated to contain a 
longer spacer by inserting a long hinge region between tbe scFvG250 and tbe CD4 
transmembrane region. A hinge sequence was selected consisting of tbe Ig heavy 
chain constant hinge-CH2-CH3 region to facilitate high level surface expression of 
chimeric receptors (162). In addition, in construct 'C' tbe JK region was shortened 
from 11 to 3 a.a. to reduce tbe flexibility of tbe scFv and to acquire a more rigid, 
TCR-like structure. These scFvG250 constructs were coupled to tbe 
signaltransducing TCR/CD3 !;-chain (fig. 4.2C and D). Finally, in order to study tbe 
effect tbat scFvG250 gene configuration may have on chimeric receptor protein 
folding, transport, membrane density and functional T lymphocyte membrane 
expression, constructs 'E', 'F' and 'G' were generated: the scFvG250 domain was 
inverted into variable kappa chain linked to tbe variable heavy chain (fig. 4.2E-G). 
Membrane expression levels of distinct scFvG250 molecules on 293T cells 
To test tbe level of membrane expression of tbe scFvG250 constructs, gene 
transfection experiments witb tbe pSTITCH scFvG250 constructs were performed in 
293T cells. The 293T cells are very suitable to quantify expression of different 
retroviral vector constructs because transfection efficiencies of 50%-70% can be 
obtained in these cells using tbe CaP04 transfection metbod. We assumed tbat 
protein folding and transport to tbe membrane of chimeric receptors in 293T cells 
would be representative for otber human cells, including activated human 
T lymphocytes. CaPO, transfection of 293T cells witb pSTITCH-scFvG250 
constructs 'A' to 'G' resulted in membrane expression of scFvG250 receptor witb 5 
out of 7 pSTITCH-scFvG250 constructs as analyzed by FACS after staining witb 
NUH-31 mAb and goat-anti-ouse Ig PE-conjugated (fig. 4.3). 
High level of membrane expression on activated human T lymphocytes by 
using pSTITCH-HKJCH2CH3CD41; construct 
To test iftbe observed difference in membrane expression oftbe scFvG250 (fig. 4.2) 
on 293T cells would also be found for activated human T lymphocytes, we 
compared the membrane expression of different scFvG250 chimeric receptors after 
gene transduction of activated human T lymphocytes witb constructs 'A' to 'E' (fig. 
4.2A-E) in pSTITCH. Gene transduction was performed as described by using 
cocultivation of OKT3-activated PBL witb 293T cells whicb produce GALV env 
pseudotyped retroviral particles. After gene transduction, clear differences in 
percentage of scFvG250 chimeric receptor positive T lymphocytes were observed by 
FACS analysis after staining witb anti-idiotype mAb (NUH-31) and goat-anti-mouse 
Ig PE-conjugated. Similar to tbe result obtained in 293T cells, activated human 
T lymphocytes transduced witb pSTITCH-HKCH2CH3CD41; construct (construct 
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'C') did not show any membrane expression of the chimeric receptor by rAGS 
analysis, nor RCC specific cytolysis (see below). To compare scFvG250 receptor 
membrane expression densities on the gene transduced T lymphocytes better we 
enriched the scFvG250'" population. This was done by positive selection of 
scFvG250-transduced T lymphocytes with NUH-31 mAb and magnetic beads coated 
with GAM !g. Chimeric receptor membrane expression was determined by FACS 
with anti-idiotype mAb NUH-82 and goat-anti-mouse Ig PE-conjugated after 
culturing the scFvG250"'' enriched T lymphocyte population for 1 week and the 
mean fluorescence channel number of scFvG250 membrane expression was 
determined (figs. 4.4A-E). Transduction of activated human T lymphocytes with 
pSTITCH-HKJCH2CH3CD4s construct resulted in the highest density of 
membrane expression of scFvG250 chimeric receptor on activated human 
T lymphocytes (fig. 4.2D). 
A. 
B. 
c. 
D. 
E. 
f·', 
.1'., 
' . 
11 I, 
,I 
figure 4.3 Cell surface e"\:Pression of scFvG250 constructs on 
293T cells. scFvG250 expression was determined by flow 
cytometry after transfection of 293T cells with different 
pSTITCH-scFvG250 constructs ('A'-'G' as indicated in fig. 
4.2). Cells were stained by indirea immunofluorescence with 
2 ).l.g/ml of the NUH-31 mAb followed by incubation with 
goat-anti-mouse Ig PE-conjugated (G.AM-PE). Data are 
presented in histograms with relative cell numbers on the y-
a."Xis and relative fluorescence intensity (FL2) on the x-axis in 
log scale. 
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ScFvG250 chimeric receptor membrane expression on activated human 
T lymphocytes results in RCC specific cytolysis 
Different densities of scFvG250 chimeric receptor membrane expression were 
observed on scFvG250 gene transduced activated human T lymphocytes (fig. 4.4A-
E). Therefore we tested the level of functional expression of scFvG250 constructs 'A' 
to 'E' on activated human T lymphocytes in cytotoxicity assays after gene 
transduction and immuno selection with NUH-31 mAb and magnetic beads (fig. 
4.5). Activated human T lymphocytes transduced with pSTITCH-HKCH2CH3CD4s 
construct (fig. 4.2C) that did not show membrane expression of the chimeric 
receptor did not lyse G250 Ag''" RCC. Activated human T lymphocytes transduced 
with the 4 other constructs demonstrated high levels of G250 Ag'"' RCC-specific 
lysis. Despite the different membrane expression densities, levels of RCC-specific 
cytolysis were similar. 
A. 
J'i1l 
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figure 4.4 Cell surface expression of scFvG250 construct on 
activated human T lymphocytes. scFvG250 expression was 
determined by flow cytometry after gene transduction of 
activated human T lymphocytes with different pSTITCH-
scFvG250 constructs ('A'-'E' as indicated in fig. 4.2) after 
NUH-31 immunomagnetic selection. Gene-transduced 
T lymphocytes were stained by indirect immunofluorescence 
with NUH -82 mAb (20 )ll culture supernatant) followed by 
incubation with GAM-PE. Data are presented in histograms 
with relative cell number on the y-axis and relative 
fluorescence intensity (FL2) on the x-a.xis in log scale and the 
mean fluorescence channel is indicated for each sample. 
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figure 4.5 Cytotoxicity of pSTITCH-scFvG250-transduced activated human T lymphocytes against RCC. 
Activated human T lymphocytes, transduced with different pSTITCH-scFvG250 constructs ('A'-'E' as 
indicated in fig. 4.2) and NUH-31 irnmunomagnetic selected for scFvG250 membrane expression, were 
incubated with RCC (SK-RC-17 d4, a G250 Afbpo; RCC and SK-RC-17 cl.l, a G250 Agno;; RCC) and tested 
in a 4-h 51 Cr release assay. The specific 51Cr release is depicted at different E:T ratios. Experiments were 
performed in triplicate, and the SD did not e.xceed 10%. Similar results were obtained from at least two 
independent experiments. 
DISCUSSION 
Genetic modification of activated human T lymphocytes allows receptor structure 
analysis in relation to its function and its signaling p_athways. Moreover, it broadens 
application of human T lymphocytes in clinical adoptive immunotherapy. To this 
end, an efficient gene transduction system is required. Here we describe the 
development of a transient gene transduction system 'STITCH' that efficiendy 
introduces genes into activated human T lymphocytes. This will ultimately allow to 
study: the influence of scFv gene structure; the distinct phases of gene transduction 
efficiency; DNA transcription; protein folding; intracellular transport; membrane 
expression; affinity of Ag recognition and signaltransduction mechanisms. 
Transfection of pSTITCH retroviral vector, a GAL V env gene construct and 
MoMLV gag-pol gene plasmids into 293T cells, resulted in production of retroviral 
vector particles with a titer of 107 c.f.u./ml in less than one week. High titer 
production of retroviral vector particles was the result of the combination of vector 
and packaging cell line in a transient virus producing system. Transient systems have 
been described earlier but are either not available for clinical applications or could 
be improved by increase of virus titer by incorporation of the SV 40 ori in the 
retroviral vector (220-223). 
pSTITCH was constructed to contain the SFG vector regions that increases the titer 
of virus production, as well as expression level of the gene transduced in the cells as 
earlier described for MFG retroviral vector (64, 233). Indeed, comparison of 
scFvG250 chimeric receptor gene expression in both LXSN and pSTITCH retroviral 
vector clearly showed a higher level of chimeric receptor expression using pSTITCH 
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retroviral vector. Addition of CMV promoter and SV 40 on m pSTITCH was 
expected to result in high level of protein production due to efficient CMV 
promoter regulated transcription and SV40 large T induced amplification of plasmid 
template in 293T cells (222, 229). Together these features make pSTITCH vector 
very applicable for use in a transient packaging system using 293T cells. In addition 
to high titer production of retroviral particles, the efficiency of gene transduction is 
determined by the susceptibility of the type of target cell, e.g. activated human 
T lymphocytes, for gene transduction with the retrovirus. The receptor for GAL V 
env viruses is expressed on hemopoietic stemcells at high levels and better gene 
transduction efficiencies were demonstrated in activated human T lymphocytes 
(224, 225). We showed higher gene transduction efficiency with GALV env 
pseudo typed retroviral particles in activated human T lymphocytes derived from 6 
individuals, demonstrating that this increased gene transduction efficiency is not 
donor-dependent. 
We reported earlier the construction and functional expression of a scFvG250 
construct in activated human T lymphocytes using the retroviral vector LXSN (163). 
Although we observed high levels of RCC-specific scFvG250-redirected cytolysis, the 
level of chimeric receptor surface expression on the gene-transduced T lymphocytes 
was too low for detection by FACS analysis with anti-idiotype mAb. High level 
expression of the chimeric receptor would have several advantages because it will 
allow immunoselection of receptor expressing cells and structure-function analysis. 
Furthermore, it may improve cytolytic recycling capacity of the T lymphocyte. 
Functional membrane expression of chimeric receptors is a result of both gene 
transcription regulated by the retroviral vector and structure of the inserted chimeric 
receptor gene. The inserted gene must be translated into a protein, folded into the 
right configuration, passed through the endoplasmic reticulum control mechanism, 
transported to the membrane, e>:pressed on the membrane and finally recognize Ag 
and transduce a functional signal into the T lymphocyte. We assume that man-made 
molecules like scFv chimeric receptors might not always fold in the right 
configuration and therefore may become degraded in the endoplasmic reticulum 
(234). To study the effect of scFv gene structure on the membrane expression of the 
chimeric Ig receptor receptors we generated 7 different scFvG250 constructs and 
tested membrane expression on 293T cells ('A' to 'G') and activated human 
T lymphocytes ('A' to 'E') with pSTITCH retroviral vector. For 5 out of the 7 
scFvG250 gene constructs, gene transfers resulted in membrane eA.'Pression on 293T 
cells, showing that these 5 gene products were properly folded. ScFvG250 membrane 
expression on 293T cells appeared representative for expression on the membrane 
of activated human T lymphocytes. To study membrane expression profiles of the 
different scFvG250 gene structures, transduced T lymphocytes were enriched using 
immuno selection with anti-idiotype mAb coated magnetic beads. FACS staining 
with anti-idiotype mAb of the enriched fractions showed different fluorescence 
profiles. Activated human T lymphocytes transduced with pSTITCH-
HKJCH2CH3CD4s (construct 'D') showed the highest density of chimeric receptor 
70 
membrane expression. Removal of 8 a.a. of the G250 JK region in this scFvG250 
construct completely abrogated scFvG250 membrane expression and function 
(construct 'C'). Hence, the presence of the complete JK gene region appears essential 
for functional membrane expression of scFvG250 chimeric receptors. Replacement 
the 15 a.a. spacer region in construct 'A' by an Ig heavy chain constant hinge-CH2-
CH3 region (construct 'D)) resulted in an even more dense membrane expression 
on activated human T lymphocytes. We conclude that a small spacer sequence (15 
a.a.) together with the complete Ig joining region is already sufficient for functional 
membrane expression of scFvG250 chimeric receptors. However, other, larger hinge 
regions, may result in distinct and higher levels of membrane expression. Moreover, 
the different profiles in membrane expression of the scFvG250 may also reflect 
differences in gene transfer efficiencies for the scFvG250 constructs. 
ScFvG250 mediated antigen recognition and signaltransduction triggered specific 
cytolysis by these T lymphocytes as was determined in short term 51Cr release assays. 
Four out of five scFvG250 chimeric receptors were functionally expressed on the 
activated human T lymphocytes and triggered T cell cytotoxicity. The levels of lytic 
activity were similar despite the differences in membrane density. These findings 
confirm our earlier observation that even at FACS undetectable levels of scFvG250 
chimeric receptor membrane expression on T lymphocytes of a panel of five 
different RCC lines were specifically lysed by these scFvG250 gene-transduced 
T lymphocytes (163). 
In conclusion, the 'STITCH' gene transduction system is efficient in (a) expressing 
gene constructs in 293T cells for rapid screening of membrane expression; (b) 
production of high titer of retroviral vectors; and (c) introduction of genes and 
relatively high levels of gene expression in activated human T lymphocytes. We 
demonstrated efficient gene transduction of optimized scFvG250 chimeric gene 
constructs in these activated human T lymphocytes, resulting in high density of 
chimeric receptor membrane expression. Specific cytolysis of cancer cells expressing 
the relevant antigens was observed. These findings open the way to clinical 
application with chimeric receptors engineered human T lymphocytes. A clinical 
phase !/II study is in preparation. 
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SUMMARY 
Genetically engineered expression of tumor-specific single chain antibody chimeric 
receptors (ch-Rec) on human T lymphocytes endow these cells with the parental 
monoclonal antibody (mAb) dictated tumor specificity and may be useful for 
clinical immune-gene therapy. Therefore it was of importance to assess how the 
densities of tumor-specific receptors and tumor associated antigens (TAA), 
respectively, affect primary human T lymphocyte functions in relation to target cell 
susceptibilities to lysis. We therefore studied the functional balance between ch-Rec 
densities on human T lymphocytes and TAA on tnmor cells. The gene construct 
encoding-a ch-Rec derived from (a) a renal carcinoma cell (RCC) specific mouse 
mAb (G250), and (b) the human signal transducing Fc(•)RI y-chain was used. To 
obtain ch-RecHIGH-POs and ch-RecLow-Pos T lymphocytes, 2 distinct retroviral vectors 
were used to introduce the gene constructs into primary human T lymphocytes. 
Levels of ch-Rec-redirected T lymphocyte mediated tnmor cell lysis as well as 
lymphokine production were determined using RCC lines as target/stimulator cells, 
which express either no or increasing densities of the TAA. A functional and 
dynamic balance between ch-Rec densities on cytotoxic Tlymphocytes (CTLs) on 
the one hand and TAA densities on RCCs on the other, was found. In short, ch-
RecHIGH-POS CTLs are triggered by TAA HIGH-Pos as well as TAA ww-Pos RCCs to lyse 
tumor cells and produce (IFN-y and TNF-a) lymphokine. In contrast, ch-Recww.pos 
T lymphocytes are ouly triggered for cytolysis and lymphokine production by 
relatively TAAHIGH-Pos RCCs. In conclusion, (a) the activation ofT lymphocyte 
responses is co-determined by the expression levels of the ch-Rec on T lymphocytes 
and the TAA on tumor cells and (b) at relatively high T lymphocyte ch-Rec 
expression levels the CTLs lyse tumor cells with a wide range ofTAA densities. 
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INTRODUCTION 
Immune responses ofT lymphocytes result from binding ofT cell receptors (TCRs) 
on T lymphocytes to major histocompatibility complex (MHC) I antigen complexes 
on target cells. This binding leads to TCR-mediated signal transduction and 
activation of effector functions such as cytolysis and lymphokine production (3S, 
23S). The quantity as well as quality of the functional immune responses are affected 
by these TCR I antigen interactions. In a model system, T lymphocyte function was 
triggered in vitro by bispecific mAbs (bsmAbs), that interact with the CD3 complex 
on T lymphocytes and TAA on tumor cells, respectively (138, 14S). We and others 
showed that the level of activation of a T lymphocyte function, e.g. cytolysis, is 
positively correlated with the amount ofbsmAb cross-linking TCRs and activation I 
target antigens (36, 37, 236), and that following TCR/CD3 complex engagement 
with these antigens, TCRs on a single CTL that were triggered, become inactivated 
and degraded (ISO, 237). Hence, CTLs serially use sets of TCR/CD3 complex for 
antigen engagement and can serially lyse multiple target cells (ISO). However, 
T lymphocytes are not triggered to exert the full range ofT cell functions at very low 
antigen densities. Also) different antigen densities or potencies result in different 
levels of TCR engagements and are elicit for the triggering of distinct effector 
functions (ISO, 238-241). The limited data that are available on the effect of low 
versus high TCR densities on antigen reactive T lymphocyte responses show a 
correlation with T lymphocyte activities (239, 241, 242). A detailed understanding of 
the functional balance between TCR and TAA densities is therefore essential for the 
generation of optimally anti-tumor reactive T lymphocytes for cancer gene-
immunotherapy now that adoptive transfer of tumor-specific CTLs to patients has 
demonstrated clinical benefit. However, specific CTLs from patients are difficult to 
isolate and cumbersome to expand to therapeutic numbers and this critically limits 
their clinical application (44). Fortunately genetic programming of CD3Pos 
T lymphocytes specificity for TAA can be achieved by retroviral transfer of 
transgenes encoding for a tumor specific mAb-derived ch-Rec (!54, 243, 244). Such 
ch-Rec consists of a mAb-based single chain antibody (scFv), coupled to a Fc(c)Rl y-
chain or CD31;-chain, and these ch-Rec can functionally be expressed in the 
membrane of primary human T lymphocytes (161-163, 24S, 246). As for 
endogenous TCRs, binding of ch-Rec to relevant TAA results in activation of 
lymphocyte functions, e.g. target cell lysis and lymphokine production (ISS, 161-
163, 24S, 246). The ch-Rec-mediated antigen binding is MHC-unrestricted and of 
high affinity. Moreover, adoptive transfer of genetically engineered ch-RecPos CTLs 
has shown in vivo anti-tumor activity in mice (166-168). 
We used a chimeric mAb-based receptor derived from the G250 mAb which 
specifically recognizes G2SO TAA on RCCs (247). Ch-Rec gene-transduced primary 
human CD3ros T lymphocytes specifically: (a) recognize and lyse RCCs in an MHC-
unrestricted fashion, and (b) produce lymphokines during interaction with RCCs, in 
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spite of the fact that the ch-Rec density was too low to be detected by flow 
cytometric analysis (163, 245, 246). In order to optimize the generation of primary. 
human CTLs with genetically engineered tumor specificity and anti-tumor activity, 
we developed a retroviral vector system that produces high gene expression and high 
membrane expression of the ch-Rec by primary human T lymphocytes (246). 
Because tumor cells in vivo express TAA at varying densities we determined how 
different densities of TAA tumor cells on the one hand and ch-Rec and 
T lymphocytes on the other affect the quantity and quality of T lymphocyte 
responses, which are important in anti-cancer immune activities. 
We demonstrated that distinct TAA surface expression levels on tumor cells are 
required for triggering of ch-Recww ·versusHIGH-POs primary T lymphocyte functions. 
In short, ch-RecHIGH-PosT lymphocytes can be triggered for cytolysis and lymphokine 
production by both G250 TAA HIGH-Pos as well as LOw-Pos RCCs. In contrast, ch-
Rec-ow-Pos T lymphocytes are only activated by TAAHIGH-POS but not LOw-ros RCCs. 
Hence, the activation level of a CTL is co-determined by TAA as well as ch-Rec cell 
surface densities. To minimize the chance that TAALOW-Pos tumor cells escape from 
immune recognition by adoptively transferred T lymphocytes which are genetically 
programmed with tumor cell specificity, ch-Rec"'GH-Pos CTLs, i.e. in the range of 
physiological TCR densities, are recommended for gene-immunotherapy of cancer. 
MATERIALS AND METHODS 
Cells and antibodies. 
Peripheral blood lymphocytes (PBL) of healthy donors were isolated by 
centrifugation through Lymphoprep (d=1,077 glcm3) (Nycomed, Oslo, Norway) 
and activated in Mix-med culture medium (78% RPM! 1640 buffered with 
bicarbonate (2 gil) and HEPES (25 mM), 20% AIM-V (Gibco BRL, Paisley, UK), 2% 
heat inactivated human serum, 2 mM glutamine, 100 U/ml penicillin and 100 !lg/ml 
streptomycin), with 10 ng/ml OKT3 (Ortho, Beerse, Belgium) at a density ofO.Sx106 
cells/mi. Three days after activation, lymphocytes were washed and cultured in 
RPM! culture medium (RPM! 1640 buffered with bicarbonate (2 g/1) and HEPES 
(25 mM), 10% heat inactivated human serum, 2 mM glutamine, 100 U/ml penicillin 
and 100 !lg/ml streptomycin), supplemented with 360 IU/ml human recombinant 
IL-2 (r!L-2) (Chiron, Amsterdam, the Netherlands). 293T cells (kindly provided by 
Y. Soneoka, Oxford, UK) were cultured in DMEM medium (Bio Whittaker, V erviers, 
Belgium) containing 10% BCS (HyClone Laboratories, Logan, UT, USA), 100 U/ml 
penicillin and 100 11g/ml streptomycin. The following cell lines were used as targets 
in cytotoxicity assays: 3 clones of MHC-identical SKRC17 RCC (SKRC17-1: mock-
transfected, G250 TAANEG RCC; SKRC17-2 and -3: G250 TAA eDNA transfected 
RCC), and 4 clones of MHC-identical SKRC59 cell line (SKRC59-1: G250 TAA""c 
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RCC; SKRC59-2, -3 and -4: G250 TAA eDNA transfected RCC) (kindly provided by 
E. Oosterwijk, Nijmegen, the Netherlands). The antibodies used for FACS staining 
were: RCC antigen-specific G250 mAb (kindly provided by S. 0. Wamaar, Cento-
cor, Leiden, the Netherlands) (247) and anti-idiotype G250 mAb NUH-31 and 
NUH -82 (kindly provided by E. Oosterwijk, Nijmegen, the Netherlands) (190). 
Construction of ch-Rec retroviral vectors 
The ch-Rec gene construct HK y was made as described elsewhere ( 163) and cloned 
into the retroviral vector LXSN (186) and pSTITCH (246). For cloning into the 
vector pSTITCH, a Nco! site was introduced at the start codon using PCR. 
ch-Rec gene transduction and selection of gene-transduced human 
T lymphocytes 
Anti-CD3 activated T lymphocytes were gene-transduced with the either the LXSN 
or pSTITCH retroviral vector containing the ch-Rec construct. Gene transduction 
using LXSN was performed as described earlier (163). In short, activated human 
T lymphocytes were co-cultivated for 3 days with the irracliated L(ch-Rec)SN-
producing arnphotropic packaging cell line PA317 in the presence of 360 IU/ml r!L-
2 and 4 fl&'ml polybrene (Sigma St. Louis, MO, USA), followed by 9 days G418 
selection. LXSN-mecliated ch-Rec transduction generates ch-Red-0 w-Pos 
T lymphocytes. For pSTITCH gene transduction, retroviral particles were generated 
after transfection of 293T cells with 20 ~g of pHIT60, pCOLT-GALV and 
pSTITCH(ch-Rec) retroviral vector by using CaPO, transfection (246). After 24 
hours, transfected cells were irracliated (25 Gy) and co-cultured for 3 days with 
0,5x106 anti-CD3 activated human T lymphocytes/ml. Co-cultivation was performed 
in RPM! culture meclium (RPM! 1640 buffered with bicarbonate (2 gil) and HEPES 
(25 mM), 10% heat inactivated human serum, 2 mM glutamine, 100 U/ml penicillin 
and 100 fl&'ml streptomycin) supplemented with 360 IU/ml r!L-2 and 4 fl&'ml 
polybrene. ch-RecPos human T lymphocytes were purified by using 
immunomagnetic isolation with NUH-31 mAb (248). Gene-transduced human 
T lymphocytes were expanded in the presence of feeder cells as described previously 
(7, 187). 
Flow cytometry 
The membrane expression of G250 TAA on RCC cells and ch-Rec on human 
T lymphocytes was measured by inclirect immunofluorescence and flow cytometry 
on a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). Cells 
were washed in PBS containing I o/o BSA (PBS!BSA) and resuspended in 50 !J.] of 
PBS/1 o/oBSA. Fifty microliter of the diluted mAb was added and incubated for 30 
min at 4 oc. Cells were washed once in PBS/1 %BSA and the second step antibody 
goat-anti-mouse Ig PE conjugated was added for 30 min at 4 °C. After incubations 
cells were washed once in PBS/1 %BSA, resuspended in I o/o paraformaldehyde 
containing I fl&'ml 7-AAD (Sigma, St. Louis, MO, USA) and analyzed by flow 
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cytometry. Treatment with goat-anti-mouse Ig PE conjugated served a~-~ontrol 
staining. 
Cytotoxicity assay 
Cytotoxic activity was measured in a 51Cr-release assay. Briefly) varying numbers of 
effector cells were added in triplicate to 96-well microtiter plates (100 )lllwell), 
followed by the addition of 2500 target cells (100 ~)/well. The target cells were 
labeled with 50 !'Ci 51Cr per 0,5x106 cells for 2 h at 37 oc. At the end of the 4 h 
incubation period (37 oc and 5% C02), supernatants were collected by using a 
Skatron harvesting system (Skatron, Lier, Norway) and counted in a gamma-
counter (Wallac, Breda, the Netherlands). Percentage specific lysis was calculated as 
follows: ((test counts - spontaneous counts) I (maximum counts - spontaneous 
counts)) x 100%. Unless otherwise indicated four effector target cells (E/T) ratios 
were tested ( 60, 20, 6. 7 and 2.2). 
Measurement of lymphokine production 
To determine lymphokine production by gene-transduced human T lymphocytes 
upon antigen stimulation, 6x10' gene-transduced human T lymphocytes were 
cultured for 24 h either in the presence or absence of 2x1 O' adherent tumor cells in 
RPM! culture medium containing 360 IU/ml r!L-2. Supernatant was harvested and 
levels of TNF-a and IFN-y were measured by ELISA (Medgenix, Fleuris, Belgium) 
according to suppliers' specification. 
RESULTS 
Ch-Rec'ow-Pos CTLs can only lyse relatively G250 T AA HIGH-POS RCC 
G250 TAA densities on different RCC cell lines are shown in figure 5.1. The number 
of G250 TAA on SKRC17-2 is 16.400 (G250 TAAww.pos) and on SKRC17-3 
465.000 (G250 TAAHIGH-Pos) as determined by scatchart (Dr. E. Oosterwijk, personal 
communication). Two distinct viral vectors for ch-Rec gene transduction, LXSN and 
pSTITCH, yielded 'low' versus high expression levels of ch-Rec on primary human 
T lymphocytes (246) ('low': negative in flowcytometry but positive in ch-Rec-
mediated cytolytic assays (163)). lmmunoselection of ch-Re<f-OW-POS CTL did not 
yield ch-RecHIGH-Pos CTL as determined by flowcytometry (data not shown). 
Therefore LXSN transduced CTL were selected using G418 containing medium since 
the transgene also comprised the neomycine selection marker. Ch-RecHIGH-Pos 
T lymphocytes were selected with anti-idiotype coated magnetic beads (fig. 5.2). 
How TAA density affects signaling strength of CTL was determined by measuring 
the levels of RCC cytolysis produced by ch-RecLOw-Pos versusHIGH-Pos human CTLs. 
The following cell lines were used as targets: (a) G250 TAANEG RCCs (SKRC17-1 and 
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SKRC59-l); (b) G250 TAALOW-POS (SKRC17-2) and (c) HIGH"'05 RCCs (SKRC17-3, 
SKRC59-2, SKRC59-3 and SKRC59-4; fig. 5.1). As expected, mock transduced CTLs 
did not lyse G250 TAA'05 RCCs and vice versa, G250 TAANEG RCCs were not lysed 
by ch-Rec'05 CTLs (fig. 5.3A). In contrast, all relatively G250 TAAHIGH-Pos RCCs were 
readily and equally well lysed by ch-Rec'ow-Pos, i.e. no TAA dose response was 
observed (fig. 5.3A). 
Only a marginal level of lysis of G250 TAA ww.pos RCCs by ch-Rec'ow-Pos CTLs was 
observed (fig. 5.3B). To exclude that G250 TAALOw-Pos SKRC17-2 cells showed a 
G250 TAA independent resistance to CTL lysis we added bsmAb CD3xG250 to the 
CTL/RCC mixture, because bsmAbs cross-link CD3 on CTLs to G250 TAA on RCCs 
and trigger cytolysis (i40). G250 TAAww-Pos RCCs were readily lysed by the ch-
Recww-Pos CTLs sensitized with bsmAbs (fig. 5.3B). These results demonstrate that: 
(a) no 'overall resistance' explained the lack of lysis by ch-Rec10w-Pos CTLs, and (b) 
G250 TAA were expressed by SKRC17 -2 RCCs, as already demonstrated by scatchart 
analysis (E. Oosterwijk, personal communication). The G250 TAAHIGH-Pos RCC cell 
lines showed increased densities of G250 TAA, but no TAA dose response was 
observed in combination with ch-RecLow-Pos CTLs. 
200 400 600 800 1000 
G250 mAb/GAM-PE----+-
figure 5.1 Cell surface expression densities of G250 TAA on RCC. G250 TAA expression was determined 
by flow cytometry on the following RCCs SKRC17-l, SKRC17-2, SKRC17-3, SKRC59-l, SKRC59-2, 
SKRC59-3 and SKRC59-4. RCCs were stained by indirect immunofluorescence with 2 IJ.g/ml of G250 
mAb followed by incubation with goat-anti-mouse PE conjugated (GAM-PE) (solid line) or by 
incubation with GAM-PE alone (dotted line). The difference in linear channel number is indicated for 
each sample (top right comer). Data are presented in histograms with relative cell number on they-axis 
and relative fluorescence intensity (FL2) on the x-axis in log scale. 
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figure 5.2 Different retroviral vectors result in distinct ch-Rec receptor expression levels on human 
T lymphocytes. ch-Rec expression was determined by flow cytometry after gene transduction of human 
T lymphocytes with (A) LXSN-HKy and (B) pSTITCH-HKy. Gene-transduced human T lymphocytes 
were stained by indirect immunofluorescence with 2 flg!ml of the NUH-82 mAb followed by incubation 
with goat-anti-mouse PE conjugated (GAM-PE) (solid line) or by incubation with GAM-PE alone 
(dotted line). Data are presented in histograms with relative cell number on they-axis and relative 
fluorescence intensity (FL2) on the x-axi.s in log scale. 
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figure 5.3 Cytotoxicity of ch-Rec gene-transduced human T lymphocytes against RCCs with distinct G250 
TAA membrane expression densities. LXSN-HKy gene-transduced human T lymphocytes (ch-Re<fOW-Pos 
CTL) were incubated with the following RCCs: (A) SKRC59-l (G250 TAA"EG RCC), SKRC59-2, 
SKRC59-3 and SKRC59-4 (G250 TAAPOS, gene transfected RCC), and (B) SKRC17-1 (mock-transfected 
G250 TAA*0 RCCs), SKRC17-2 (G250 TAA ros, gene transfected RCCs) and tested in a 4-h 51Cr release 
assay. BsmAb CD3xG250 (1:5000) was added to the effector/target (E/T) reaction mixture where 
indicated. The specific 51Cr release is depicted at different E/T ratios. Experiments were performed in 
triplicate, and the SD did not exceed 10%. Similar results were obtained from at least two independent 
experiments. 
Ch-Rec"'GH-POs CTLs lyse G250 T AA ww-Pos as well as G250 T AA HIGH-Pos RCCs 
The lack of significant lysis of G250 TAA ww-Pos RCCs by ch-Red-0w-Pos CTLs might 
be compensated for by using CTLs with increased ch-Rec surface densities. 
Therefore tvvo retroviral vectors were used in parallel to introduce the same ch-Rec 
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gene construct into human T lymphocytes derived from the same donor blood 
sample, LXSN and pSTITCH, respectively (163, 246). The ch-Recww -Pos and HIGH-POS 
primary human T lymphocyte populations were then used as effector cells against 
G250 (a) TAANE0 , (b) TAAww-Pos and (c) TAAHIGH-Pos target cells (fig. 5.2). G250 
TAA10w.,os RCCs, that were not lysed by ch-Red-ow-Pos CTLs (see above), were 
efficiently lysed by ch-RecHIGH-Pos CTLs (fig. 5.4), whereas G250 TAAHIGH-Pos RCCs 
were readily lysed by both ch-Recww-Pos andHIGH-POs CTLs. In the combination ch-
RecHIGH-POS CTL G250 TAA HIGH-Pos RCC lines with increasing TAA densities a TAA 
dose response curve for CTL lytic activity is observed: the higher the TAA density 
the higher the percent RCC lysis (fig. 5.4B). Expectedly, mock transduced CTLs did 
not lyse G250 TAAHIGH-Pos or ww-Pos RCCs and ch-Rec'05 CTLs did not lyse G250 
TAANEG RCCs. 
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figure 5.4 ch-RecHIGH-POS CTLs can lyse TAA10w-POS twnor cells. LXSN-HKy (A) and pSTITCH-HKy (B) 
gene-transduced human T lymphocytes e."<Pressing low or high ch-Rec receptor densities, respectively, 
were incubated v..-i.th RCC SKRC17-l (mock-transfected G250 TAA"'EG RCC), SKRC17-2 (G250 TAAtow-
POs, gene transfected RCC) and SKRC17-3 (G250 TAAHIGH-POs, gene transfected RCC), and tested in a 4-h 
51 Cr release assay. The specific 51 Cr release is depicted at different E/T ratios. Experiments were performed 
in triplicate, and the SD did not exceed 10%. Similar results were obtained from at least two independent 
experiments. 
To illustrate further the functional balance between ch-Rec and G250 TAA densities, 
we determined the levels of G250 TAAHIGH-Pos RCC lysis in the absence and presence 
of increasing concentrations of parental G250 mAb. G250 TAANE0 , TAAww.pos and 
TAAHIGH·POs RCC cell lines cloned from parental SKRC17 cell line, and hence MHC 
identical, were used as target cells. By adding increasing concentrations of parental 
G250 mAb the number of free G250 TAA accessible for ch-Rec'05 receptor 
engagement becomes gradually decreased mimicking decreasing TAA densities. Even 
high concentrations ( 10-50 !!-g) of 'blocking' G250 mAb cannot totally block the lysis 
of G250 TAAHIGH·POS RCC by ch-Rec'flGH-Pos CTLs. In conclusion, the higher the 
concentrations of blocking G250 mAb present the less G250 TAA is accessible for 
ch-Rec engagement as reflected by lower levels of target cell lysis (fig. 5.5). This is 
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further substantiated by tbe fact that lysis of TAA LOw-Pos RCC by ch-RecHIGH-POS CTL 
can be blocked by as little as 5 ~ml of G250 mAb. This observed TAA dose 
response curve for ch-RecHIGH~Pos CTL lytic activity confirms the dose-response 
results presented in figs 4A and 4B. From tbe results shown in figure 5.5 (hatched 
bars) it can also be concluded tbat tbe more TAA are available for ch-Rec 
engagement the higher the percent tumor cell lysis occurs per unit time) provided 
tbat tbe density of free TCRs on CTLs is not limiting, i.e. only in combination witb 
ch-RecHIGH-Pos CTLs. Lysis of G250 TAAmGH-Pos RCCs by ch-Rec10w-Pos CTL was 
already blocked at 1 Mg/ml of G250 mAb. For comparison, only partial inhibition of 
lysis of G250 TAAHIGH-POs RCCs (SKRC17-3) by ch-RecHIGH-Pos CTLs already 
required a 50 times higher concentration of G250 mAb. 
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figure 5.5 Gene-transduced T lymphocytes with low ch-Rec membrane density are more sensitive to 
inhibition of cytolysis with G250 mAb. RCCs SKRC17-3 and SKRC17-2 target cells were incubated with 
or without various concentration of G250 mA.b. Cytolysis of SKRC17 -1 (mock-transfected G250 T .AA NEG 
RCC), SKRC17-2 (G250 TAALOW-POS, gene-transfected RCCs) and SKRC17-3 (G250 TA.A.HrGH-ros, gene-
transfected RCCs) by ch-RecLOW-POS and ch-Red~!GH-POS en was measured in a 4-h 51Cr release assay. 
Blocking of cytolysis with G250 mAb was performed at the indicated concentrations. The specific 51 Cr 
release is depicted at an E/T of 20. E.xperiments were performed in triplicate, and the SD did not exceed 
10%. Similar results were obtained from two independent experiments. 
Kinetics of tumor cell lysis do not depend on chimeric receptor density 
Now tbat tbe functional balance between ch-Rec densities on CTLs and of TAA on 
tumor cells in relation to triggering of effector functions has been shown, we 
investigated tbe effect ofTAA density on tbe kinetics of target cell lysis. Ch-Rec10w 
and HIGH-POs CTLs were mixed witb G250 TAA'"0 , G250 TAALOW-POS and G250 
TAAHIGH-Pos RCCs for 2, 4, 6 and 8 h respectively (fig. 5.6). Again, tbe percentage of 
RCCs lysed per unit of time correlated with tbe G250 TAA density on tbe RCCs, 
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provided the ch-Rec density was not limiting, i.e. in combination with ch-RecHIGH-Pos 
CTLs. Neither ch-Re<f-Ow-Pos nor HIGH-Pos CTLs reached plateau levels of RCC lysis 
during up to 8 hrs of incubation with RCC, irrespective of their G250 TAA 
expression level. 
Chimeric receptor and TAA densities also co-determine levels of 
T lymphocyte IFN-"( and TN F-a production 
Individual CTLs can exercise distinct biological responses as a function of 
percentage ofTCR occupancy (ISO, 238-242), which in tum is determined by ligand 
density and potency (240). Therefore we studied the capacity of ch-Recww and 
HIGH-PosT lymphocytes to secrete INF-y and TNF-cx in response to G250 TAAww and 
HIGH-Pos RCCs. For lymphokine production the same functional balance was seen 
between the densities of ch-Rec receptors and G250 TAA as for cytolysis. G250 
TAAww and HIGH-Pos RCCs induce IFN-y and TNF-cx production in ch-RecHIGH-Pos 
CTLs. G250 TAA HIGH-POS induced higher lymphokine concentrations than G250 
TAAww-Pos RCCs (table 5.1). Only G250 TAAHIGH-Pos RCC but not G250 TAALOw-Pos 
RCCs induced IFN-y and TNF-cx production in ch-Recww-Pos CTLs. G250 TAANEG 
RCCs did not induce lymphokines in any ofthe ch-RecPos CTLs. 
table 5.1 TNF-o: and IFN-y secretion of gene-transduced T lymphocytes upon target cell interaction" 
TNF-cx 
G250 TAANEG G250 T AA LOW-POS G250 T AA HIGH-POS 
effector (SKRC17-1) (SKRC17-2) (SKRC17-3) 
ch-RecL0\111-POs CTLs <12 25 480 14 
(LXSNHKy) 
ch-RecHIGH-POs CTL.s 35 274 4440 145 
(pSTHKy) 
IFN-y 
G250 TAANEG G250 TAALOW-POS G250 T AA HIGfi..POS 
effector (SKRC17-1) (SKRC17-2) (SKRC17-3) 
ch-RecLow-POs CTLs <12 <12 125 <12 
(LXSNHKy) 
Ch-RecHIGH-ros CTLs <12 143 346 17 
(pSTHKy) 
"Six times 104 T lymphocytes transduced with ch-Recly (ch-RecLOW-POSand HrGHPOS CTLs) were cultured in 
medium or with 2xl04 G250 mAb-binding or non-binding tumor cells, for 24 h. Lymphokine secretion in 
supernatant was measured by ELISA (Medgenix, Brussels, Belgium). Background lymphokine secretion 
by tumor cells was < 1 pglml for TNF-c.x and < 0,2 IU/ml for IFN-y. Production of TNF-o: is in 
pglml/3x105 cells/24 hand ofiFN-y in IU/ml/3xl05 cells/24 h. Results were obtained from 2 independent 
experiments. alstimulator: SKRCI7-I =a G250 TAANEG human renal carcinoma cell clone; SKRCI7-2 = 
G250 TAAww.ros human renal carcinoma cell clone; SKRCI7-3 = G250 TAAHIGRPos human RCC 
clone; - = no stimulator cell. 
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figure 5.6 Kinetics ofRCC specific lysis by T lymphocytes with low and high density of ch~Rec membrane 
expression. Ch~RecLOw-POs and ch~RecHIGIHOs en were incubated with (A) SKR.C17~1 (mock~ 
transfected G250 TA.t\.NEG RCC), {B) SKRC17~2 {G250 TA.t\.ww-ros, gene transfected RCC) and (C) 
SKRC17~3 (G250 TA.t\.HIGH-ros, gene transfected RCC), and tested in a 2, 4, 6 and 8h 51Cr release assay. 
The specific 51Cr release is depicted at different E/T ratios. Experiments were performed in triplicate, and 
SD did not exceed 10%. 
DISCUSSION 
Major functions of CD8'05 T cells are to exert cellular activity in order to kill cancer 
cells or virally infected cells and to produce cytokines that influence both their own 
performances as well as those of other cell types (35). The different T lymphocyte 
effector responses that can be elicited, i.e. quality and magnitude of the response, 
depend on the density of the T lymphocyte receptors as well as on target cell density 
(238-242). A detailed understanding of antigen-receptor I antigen relationships is 
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important for the efficient generation and expansion of optimally reactive, tumor-
specific CTLs for immunotherapy, since adoptive transfer of tumor-specific CTLs 
has shown significant clinical benefit (44, 244). However, tumor-specific CTLs are 
difficult to isolate from cancer patients and their expansion to therapeutic numbers 
is time-consuming and the succes rate unpredictable. 
Fortunately, genetic programming of T lymphocyte specificity is now possible by 
(retro)viral transfer of genes encoding mAb-based ch-Rec with a chosen TAA 
specificity. Engagement of such ch-Rec with TAA results in triggering of human 
T lymphocyte responses such as tumor cell lysis and tumor cells triggered 
lymphokine production (155, 161-163, 245, 246). This molecular approach offers 
fundamental new opportunities for gene-immunotherapy (244). In an earlier report 
on native TCR/CD3 complex functions we showed that individual human CTLs 
serially use sets of TCR/CD3 complexes to engage target TAA and that following 
signal transduction the disengaged TCR/CD3 complexes become inactivated and 
degraded (150, 237). Prior unengaged TCRs on the same T lymphocyte can engage 
with antigens on new target cells. We proposed that this serial use of sets of TCRs 
may underlie the ability of individual CTL to serially lyse multiple target cells (150). 
Further studies showed that already small numbers of target antigens can repeatedly 
trigger increasing numbers of TCRs on an individual CTL (193, 242). The few 
reports available in the literature on the functional balance between TCR density 
and T lymphocyte response to antigens show that a decrease in TCR density results 
in reduced T lymphocyte responses (239, 241). Hence, quality and quantity of 
T lymphocyte responses depend on and differ in (a) required thresholds of TCR 
occupancies; (b) antigen densities; and (c) antigen potencies. Different 
T lymphocyte responses may require distinct signaling thresholds, in a T cell clone-
specific hierarchy (239-242, 249). During the preparation of this manuscript we 
became aware of the data recently published by Alvarez and Russell (250), who used 
a model system using Jurkat T cells with tetracycline-regulable ch-Rec densities to 
study their level of IL-2 response as a function of plastic coated antigen density. 
They concluded that Jurkat T cells can be engineered to discriminate between 
different antigen densities allowing optimization of the Jurkat T cells' response to a 
fixed concentration of antigen. Here we indeed demonstrate that their conclusion 
holds for primary human T lymphocytes expressing ch-Rec specific for native TAA 
at the level of (a) specific tumor target cell lysis; and (b) lymphokine production 
(TNF-a and IFN-y). We further investigated this functional balance between ch-Rec 
and TAA densities in relation to quantity and quality of CDS T lymphocyte 
responses. 
Primary human CD3'05 T lymphocytes transduced with ch-Rec genes using the 
LXSN retroviral vector subsequently express very low densities of ch-Rec, not 
detectable by flow cytometric analysis using anti-idiotype mAbs. Presence of the ch-
Rec was however readily detected in a sensitive 51Cr release assay by measuring 
tumor-specific cell lysis, and by quantitative assessment of lymphokine production 
(163). Here we determined the levels of both (a) tumor target cell lysis by ch-Rec'0 ' 
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CTL; and (b) lymphokine production in combinations of G250 TAA NEG. LOW and HIGH 
RCC populations and ch-Rec'-ow-Pos and HIGH-POs CTL populations. A high expression_ 
level of ch-Rec by CTLs was accomplished by using our novel pSTITCH viral vector 
(246). Now, aliquots ofT lymphocytes from the same donors were gene transduced 
with the two viral vectors LXSN and pSTITCH. These two vectors yielded low and 
high expression levels of ch-Rec in the membrane of human T lymphocytes. Because 
no qualitative or quantitative differences in the gene transduction were observed 
between lymphocyte donors the results obtained for one representative donor are 
presented. It appeared that G250 TAAww-Pos RCCs were only lysed by ch-RecHIGH-Pos 
CTLs, not by ch-Recww-Pos CTLs. In contrast, G250 TAAHIGH-POS RCCs were lysed by 
both ch-Rec'-ow-Pos and HIGH-POs CTLs. For the induction of the lymphokines INF-y 
and TNF-u the same functional balance between ch-Rec versus TAA densities were 
found. We excluded that the G250 TAAww-Pos RCCs would in fact be: (a) G250 
TAA''EG or, (b) that these RCCs showed a G250 TAA independent overall resistance 
to CTL mediated lysis. The RCCs which were functionally labeled G250 TAA ~ow-Pos·, 
in cytolytic assays, but G250 TAANEG in flowcytometric analysis, were indeed shown 
to be G250 TAALOw-Pos in (a) scatchart analysis (E. Oosterwijk, personal 
communication) and in (b) bsmAb-mediated cytolysis assays (fig. 5.3B). Differences 
in levels of lysis could not be due to alloreactivities generated in our T lymphocyte 
culture system since all SKRC cell lines used were cloned from one RCC line and 
hence MHC-identical. 
We earlier reported that both bsmAb and ch-Rec-mediated TAA recognition and 
tumor cell lysis may involve adhesion molecules such as CD 54 and CD 58, depending 
on their cell surface densities (36, 37, 245). Therefore we also needed to exclude that 
suboptimal levels of expression of CD54 and I or CD58 caused (a) the lack of ch-
Rec-mediated lysis of G250 TAAww-Pos RCC and I or (b) the lack of a G250 TAA 
dose response in combination ch-RecHIGH-Pos CTLs. Indeed, all cloned RCC lines 
tested expressed identical levels of CD 54 and CD 58 as deterniined by flow cytometry 
using the appropriate fluorochrome labeled mAbs. One could further speculate that 
only the minor 2% fraction of ch-RecHIGH-POS CTL within the ch-Recww-Pos CTL 
population was responsible for the lysis of G250 TAA HIGH-Pos RCCs. However, if this 
were true then, based on the EIT ratios presented and from cytotoxicity data shown 
in fig. 5.4, by extrapolation it follows that at an 50-fold lower EIT ratio (of about 
0.4) 70% lysis of RCCs could be induced. But as shown in fig. 5.4, for a level of 70% 
lysis of RCCs by ch-RecHIGH-POs CTLs a 10-fold higher EIT ratio is required (i.e. 
about 4). Based on these considerations and calculations we propose that above a 
density threshold, TAA are spatially positioned in the membrane, that they can be 
optimally engaged by ch-Rec on CTLs. This hypothesis may find experimental 
support in our observations that for combinations of ch-RecHIGH-Pos CTLs where ch-
Rec density is not limiting clear TAA dose responses were observed: higher levels of 
lysis and lymphokine production are induced by higher TAA densities. 
It is noteworthy that a relative over-expression of ( ch)-Rec in combination with high 
antigen density can even induce T cell apoptosis rather then T cell activation (250). 
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In short, we showed that quantity and quality of the T lymphocyte responses is co-
determined by (a) the ch-Rec density on CTLs and (b) by the TAA density on target 
cells. This functional balance is reciprocal and dynamic: high CTLs ch-Rec density 
compensates for low TAA. The use of ch-RecHIGH-Pos T lymphocytes for gene-
immunotherapy is recommended to prevent TA.A LOW-Pos tumor cells from escaping 
immune recognition and destruction ( l 00). 
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Adoptive cellular immunotherapy 
Adoptive cellular immunotherapy in cancer treatment refers to the transfer of cultured 
immune cells with anti-tumor reactivity into patients. A variety of adoptive 
immunotherapeutical strategies have been employed including infusion oflymphokine-
activated killer (LAIC) cells, tumor-infiltrating lymphocytes (TIL) and tumor-specific 
MHC-restricted cytotoxic T lymphocytes showing therapeutic responses in some cancer 
patients (122, 132, 178). Improving this response and broadening of the range of tumor 
specificity has been obtained using bispecific monoclonal antibodies (bsmAb) that 
combine lymphokine production, homing and lytic capacity ofT lymphocytes with the 
selectivity of tumor-recognizing monoclonal antibodies (137-139). In a clinical study 
involving locoregional treatment of ovarian cancer patients, with bsmAb against 
CD3 on T lymphocytes and the folate receptor on the ovarian carcinoma cells, an 
overall anti-tumor response of 27% was observed (144, 145). Although promising, 
the use of bsmAb may be hampered by the inaccessibility of solid tumors to Ab 
penetration (99) and the limited time of antibody binding to the T lymphocytes (139, 
150). To circumvent the limitations associated with bsmAb, T lymphocytes can be 
grafted with permanent Ab-dictated specificity (155, 158). This approach combines the 
humoral and cellular arm of the immune system by genetically grafting 
T lymphocytes with chimeric receptors that consist of the binding site of a tumor 
selective antibody linked to an intracellular signaling domain from a membrane-
bound receptor involved in cellular activation. Binding of the chimeric receptor to 
antigen on the tumor cell results in activation of the T lymphocytes and 
subsequently lymphokine production and cytolytic activity. The chimeric receptor 
application should enable the production of specific T lymphocytes against any 
antigen to which antibodies exist and broaden the use of specific T lymphocytes in 
adoptive immunotherapy for cancer and viral diseases. 
In this thesis the construction and functional characterization of a chimeric receptor 
against renal cell carcinoma is described. 
Functional expression of chimeric receptors on T lymphocytes 
Chimeric receptor gene structure 
To enable construction of cytotoxic T lymphocytes ( CTL) with known predefined 
antibody (Ab) specificity for adoptive immunotherapy, we constructed a chimeric 
scFv/y gene composed of the variable regions of a renal cell carcinoma selective mAb 
G250 (179, 180). These variable domains were coupled via a linker designated 212 
(!56) that consisted of glycine and serine aminoacids. The transmembrane and 
signal-transducing molecule we used was the y-chain from the mast cell Fc(e)Rl 
(181). Introduction of this chimeric receptor into CTL rendered these lymphocytes 
specific for renal cell carcinoma. We demonstrated that the transduced CTL 
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functionally express the scFv/y receptor for a prolonged period of time ( 4.5 month of 
in vitro culture), showed high levels of Ab-dictated lysis of renal cell carcinoma 
similar to that of normal CTL, and importantly, we demonstrated that these CTL 
can recycle their lytic activity. Moreover, these scFv/y-expressing T lymphocytes 
produce lymphokines upon stimulation with the relevant target cell (chapter 2). 
Although functional membrane expression was demonstrated, membrane 
expression of the chimeric receptor at the protein level could not be detected by flow 
cytometry. For screening and detection of gene-transduced T lymphocytes it would be 
advantageous to have a higher expression level of the chimeric receptor. Both retroviral 
vector and chimeric receptor gene structure can determine membrane expression level 
(162, 232, 246, 251). We designed a transient retroviral gene transduction system 
'STITCH' comprising pSTITCH retroviral vector encoding the transgene, plasmids 
encoding Moloney murine leukemia virus gag/pol and gibbon ape leukemia virus 
envelope, and the human kidney cell line 293T as a packaging line (Chapter 4). Co-
transfection of retroviral vector and packaging plasmids in 293T cells results in the 
production of GALV env pseudotyped viral particles with a titer of 107 infectious 
units/mi. The 'STITCH' gene transduction system efficiently transduces genes into 
activated human T lymphocytes resulting in high expression levels of the inserted 
gene. In addition, we designed a number of different chimeric receptor gene 
structures that vary in (a) the configuration of the variable heavy and variable light 
chain sequences; (b) the hinge domain sequence; and (c) the sequence of the 
transmembrane domain and signal-transducing cytoplasmic tail, and subsequently 
compared their membrane expression on activated human T lymphocytes (Chapter 
4). We conclude that a small spacer sequence (IS a.a.) together with the complete Ig 
joining region is already sufficient for functional membrane expression of scFvG250 
chimeric receptors. However, other, larger hinge regions, may result in distinct and 
higher levels of membrane expression. Furthermore, both y and ~-chain signaling 
molecules successfully transduced activation signals to the T lymphocyte signal-
transducing machinery. 
The role of chimeric receptor membrane expression levels 
For T cell receptors it has been described that the quality and magnitude of the 
T lymphocyte response depends on the density of the T lymphocyte receptors as well 
as on target cell antigen density (238-242). A decrease in T cell receptor (TCR) 
density has been demonstrated to result in reduced T lymphocyte responses (239, 
241). Furthermore, in a study using )urkat T cells with tetracycline-regulable 
chimeric receptor densities it has been demonstrated that )urkat T cells can 
discriminate betvveen different antigen densities resulting in different T cell 
responses (250, 252). Because tumor cells in vivo express TAA at varying densities we 
determined how different densities of TAA on tumor cells on the one hand and 
chimeric receptor on T lymphocytes on the other affect the quantity and quality of 
T lymphocyte responses, which are important in anti-cancer immune activities. 
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Therefore we investigated the functional balance between chimeric receptor 
expression and TAA densities in relation to quantity and quality of CDS 
T lymphocyte responses using T lymphocytes expressing either low or higb densities ... 
of chimeric receptors in the membrane (Chapter 5). It appeared that tumor cells 
expressing a low level of TAA were only lysed by T lymphocytes with higb density 
expression of chimeric receptors, not by T lymphocytes with only few chimeric 
receptors. In contrast, tumor cells with large numbers of antigen molecules on their 
membrane were lysed by T lymphocytes with either higb or low densities of chimeric 
receptor. For the induction of the lymphokines INF-y and TNF-a the same 
functional balance between chimeric receptor versus TAA densities were found. 
The use ofT lymphocytes with high density expression of chimeric receptor may be 
advantageous in clinical application to prevent that tumor cells with downregulated 
antigen expression may escape immune recognition and destruction (100). 
Interaction of chimeric receptor with adhesion and co-stimulatory molecules on the 
T lymphocytes 
T lymphocytes recognize their target cells via the TCR. Interaction of CTL with 
target cells requires specific recognition of the TCR with Ag in the context of MHC 
molecules resulting in CD3 signaling, activation and subsequent effector functions 
of T lymphocytes. This specific target cell recognition is preceded by non-specific 
conjugate formation, primarily mediated by non-polymorphic cell-surface receptors 
such as CD4, CDS, CD2 and CD!la/CDIS on the T lymphocytes with their ligands 
on the target cells, i.e., MHC Class II and I, CDSS and CD54, respectively (33, 195). 
In addition to an adhesion function, the CDS, CD2 and CD11a/CD18 receptors play 
an important role in T lymphocyte activation as costimulatory molecules. 
T lymphocytes can be activated by cross-linking of CD2, CD3 or CDlla/CD18 
molecules without requiring specific TCR/CD3 interaction with MHC-peptide 
complex (16, 20, 34-38). Since adhesion and co-stimulatory molecules play a critical 
role in T lymphocyte activation and effector function, we investigated the 
contribution of CD2, CD3, CDlla/CDl8, CD54 and CD58 molecules in 
T lymphocyte-tumor interactions via the chimeric receptor (Chapter 3). A co-
regulatory role for CD2, CD3 and CDlla!CDlS molecules in chimeric receptor 
mediated lysis was demonstrated as the binding of mAbs, specific for these surface 
markers, inhibited chimeric receptor-mediated lysis of RCC. This indicated that 
chimeric receptors interact with other molecules on T lymphocytes in a similar 
fashion as the native T cell receptor. Moreover, CTL/target cell CDlla/CDl8-CD54 
interactions were required only when the RCC expressed low or intermediate levels 
of G250 Ag but not at high Ag density. For immunotherapy of cancer this may prove 
an important advantage, for it allows killing of tumor cells in patient's with 
circulating CD54 and of tumor cells with low or no CD54 expression (208, 209). 
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Therapeutic application of chimeric receptor-redirected T lymphocytes 
Experimental data from this thesis and others have demonstrated that chimeric 
receptors can redirect T lymphocytes towards tumor cells and subsequently trigger 
cytolysis and lymphokine production. To test the in vivo function and efficacy of the 
chimeric receptor approach, suitable animal models have been developed that 
showed inhibition of tumor growth, reduction in lung metastases, increased survival 
and homing to the tumor and even complete tumor regression in nude and 
syngeneic mice models ( 165, 166, 168, 170-172). Both in vitro and in vivo 
e>:periments form the basis of the development of protocols for the treatment of 
human tumors. 
3. activation f T lymphocyte~ 
2. removal and purification of 
peripheral blood lymphocytes 
4. retroviral transduction 
ofT lymphocytes 
with RCC spedfc 
I 
1. Histological analysis 
of tumor 
gene construct 
" 5. culturing and relnfuslon of 
RCC specific T lymphocytes 
figure 6.1 Immune-gene therapy protocol for the treatment of RCC vvith chimeric receptor gene -
transduced T lymphocytes. Peripheral blood lymphocytes are isolated from the patients, activated and 
gene transduced with retroviral vector containing the chimeric receptor gene. Gene-transduced 
T lymphocytes are cultured and reinfused into the patient were they should home to the tumor and 
eliminated the tumor cells. 
Immuno-gene therapy protocol 
A possible protocol for the treatment of human cancer with redirected autologous 
T lymphocytes is depicted in figure 6.1. The presence of a particular tumor antigen 
should be confirmed histologically and the expression of this antigen should be 
restricted to tumor cells to prevent induction of possible autoimmune reaction 
against self-antigens (253). With the available tumor-selective mAb or TCR a 
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chimeric receptor construct can be composed and cloned into a retroviral vector. 
The availability of a vector with a universal framework structure for chimeric 
receptors would make the gene construction of chimeric receptors fast and easy 
(244). Next, peripheral blood lymphocytes will be taken from the patients, 
stimulated in vitro using anti-CD3 antibodies and transduced with a retroviral 
vector containing the chimeric receptor gene specific for the patients TAA. The use 
of retroviral vectors with high transduction efficiencies in human PBL (224, 246, 
254, 255) would be advantageous for it would allow direct reinfusion of the 
redirected T lymphocytes that shortens the overall procedure and the heterogenicity 
of the PBL population will be conserved (256). After reinfusion, the redirected 
T lymphocytes should home to the tumor site and, upon tumor cell encounter, 
produce lymphokines to recruit other components of the immune system and kill 
tumor cells. 
Future prospects 
T lymphocytes can now be grafted with mAb-based specificity as well as TCR-based 
specificity redirecting them to antigens on target cells and MHC class I presented 
peptides respectively (163, 176). Depending on the tumor antigen expression, i.e. 
MHC-restricted or not, each tumor demands a different chimeric receptor type. 
However, the choice of chimeric receptors is limited by the availability of tumor-
specific antibodies and of TCR from tumor-specific T lymphocytes that are still 
difficult to generate due to their low frequency. The phage display technique can 
provide a pool of tumor antigen reactive molecules with potential use in the 
chimeric receptor approach (257). Large antibody Fab fragments and TCR libraries 
can be screened for molecules that bind to tumor cells (258, 259). These molecules 
can be genetically coupled to a T lymphocyte intracellular signaling molecule and 
transduced into T lymphocytes conferring either MHC-restricted and non-MHC-
restricted tumor specificity. The use of a pool of various chimeric receptors against 
different tumor antigens would be advantageous for treatment since it allows the 
elimination of tumor cells with heterogenous antigen expression patterns and of 
antigen-loss variants that might otherwise escape immune rejection. 
The clinical applicability of chimeric receptors could further be extended by using, 
in addition to T lymphocytes as anti-tumor effector cell, other cells such as 
neutrophils, NK cells, yo T lymphocytes and monocytes (173). Their homing pattern, 
cytokine repertoire and cytolytic mechanism differ from T lymphocytes and thereby 
can target different tumor cells and attract particular components of the immune 
system. In a mouse model the transduction of bone marrow cells with chimeric 
receptor genes resulted in expression of the chimeric receptor in T lymphocytes, NK 
cells, granulocytes and macrophages, and a significant in vivo anti-tumor activity 
was observed. In vivo depletion ofT lymphocytes did not diminish the anti-tumor 
reactivity suggesting that the non-T lymphocytes play an important role in the 
tumor regression (172). 
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Ongoing studies on the efficacy of the combination of multiple chimeric receptors 
and various effector cells v.rill demonstrate their potential in cancer treatment 
Final remarks 
Chimeric receptors with specificity for defined tumor antigens are valuable tools for 
targeting T lymphocytes to tumor cells. Now functional construction of chimeric 
receptors is technically possible, efficient gene-transduction systems are available 
and experimental animal studies have shown anti-tumor reactivity, the first clinical 
trials with retargeted T lymphocytes have started. In these trials the safety of 
infusions with chimeric receptor gene-transduced T lymphocytes will be determined 
and appearance, persistence and homing to the tumor of retargeted T lymphocytes 
in the body will be studied. These clinical trials will contribute to the design of 
optimal chimeric receptors and treatment protocols. 
The coming years will reveal whether the chimeric receptor approach has potential 
in the treatment of cancer patients. 
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lmmunotherapie van kanker 
Het afweersysteem biedt bescherming tegen infectieuze agentia zeals bacterien, 
virussen en parasieten. Vreemde moleculen (antigenen) kunnen worden herkend 
door het immuunsysteem en veroorzaken een afweerrespons die leidt tot de 
vernietiging van de indringers of zieke cellen. Tumorcellen kunnen zich ook 
onderscheiden van gezonde cellen door aOOjkende expressie van genetische 
informatie. Desondanks worden de tumorcellen soms genegeerd door het 
afweersysteem en kan er kanker ontstaan. Immunotherapie als behandelings-
methode is er op gericht het natuurlijke afvveersysteem van de patient zo te 
stimuleren dat de tumorcellen opgeruimd worden. 
Het afweersysteem 
Het afw-eersysteem bestaat uit een humorale en een cellulaire component. De 
hurnorale component Ievert antistoffen die een belangrijke rol spelen bij de afweer 
tegen bacterien en andere lichaamsvreemde stoffen en organismen. De cellulaire 
component bestaat onder meer uit T -lymfocyten die een rol spelen bij de afweer 
tegen micro-organismen zoals virussen die de eel indringen en waarvan aileen kleine 
stukjes eiwit op de celwand zichtbaar zijn. Beide componenten kunnen ook een rol 
spelen in de tumorafi.veer. Antistoffen tegen tumorcellen zijn eenvouclig te 
verkrijgen door muizen te immuniseren met humane tumorcellen en vervolgens 
antistoffen uit het serum te isoleren. Helaas zijn antistoffen vaak niet werkzaam 
gebleken in de behandeling van solide turnoren. T -lymfocyten zijn daarentegen beter 
in staat solide tumoren binnen te dringen maar het is vaak moeilijk om T-
lymfocyten specifi.ek voor een bepaalde tumor te isoleren uit het bloed en op te 
1..-weken voor therapie. Een combinatie van antistofherkenning en T -lymfocyt-
effectiviteit zou kunnen leiden tot een krachtig anti-turnoreffect. 
Functionele expressie van chimere receptoren op T-lymfocyten 
In dit proefschrift wordt een mogelijke therapeutische benadering beschreven voor 
de behandeling van nierkanker. De therapie combineert het hurnorale (antistoffen) 
en cellulaire (T-lymfocyten) afweersysteem om een optimaal anti-tumoreffect te 
verkrijgen. Door op het celmembraan van T-lymfocyten een niercarcinoom-
specifieke receptor te plaatsen kunnen deze T -lymfocyten nierturnorcellen 
herkennen en vervolgens opruimen door de cellen te lyseren of stoffen te 
produceren die weer andere afw"eercellen kunnen aantrekken. Zo'n niercarcinoom-
specifieke receptor moet instaat zijn een eiwit op de niertumorcellen te herkennen, 
te binden en een signaal door te geven naar de T -lymfocyt zodat die zijn 
opruimfunctie kan nitoefenen. Om deze receptor permanent op de T -lymfocyten tot 
expressie te brengen wordt de T -lymfocyt genetisch veranderd m.b.v. retrovirale 
gentransductie. Een methode waarbij een ongevaarlijk retrovirus de genetische 
informatie bevat van de receptor en T-lymfocyten kunnen worden gei:nfecteerd met 
ditvirus. Bij groei van de T-lymfocyten wordt de genetische informatie doorgegeven 
aan de dochtercellen zodat de nieuwe specificiteit aanwezig blijft. In hoofdstuk 2 is 
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beschreven hoe zo'n retrovirale vector gemaakt wordt voor een specifieke receptor 
tegen niertumorcellen. Er is gebruik gemaakt van de niercarcinoom-specifieke 
antistof G250 gekoppeld aan de signaaltransducerende y-keten. Samen vormen deze 
de zogenaarnde chimere receptor. T -lymfocyten, die na transductie met retrovirale 
vectoren de chimere receptor tot expressie brengen, zijn in staat om in vitro 
niertumorcellen te herkennen en te lyseren. 
Voor optimale activatie en functie van T -lymfocyten spelen meerdere moleculen op 
de celmembraan een belangrijke rol. Dit zijn de zogenaamde adbesie en co-
stimulatoire moleculen die samen met de endogene T eel receptor (TCR) de werking 
van de T -lymfocyt bepalen. In hoofdstuk 3 is de interactie van de chimere receptor 
met andere eiwitten op de celmembraan onderzocht. Hieruit is gebleken dat de 
chirnere receptor interactie heeft met andere moleculen maar dat deze interacties 
afhaukelijk zijn van bet aanta! tumorantigenen die op de tumorcel tot expressie 
komen. Bij een hoge dichtheid van tumorantigeen is de interactie van de adbesie 
moleculen CD!la/CD!8-CD54 niet meer van belang. Dit zou een voordeel kunnen 
zijn bij de behandeling van tumoren omdat sommige tumoren weinig of geen 
expressie vertonen van het adhesiemolecuul CD54. Ook zijn in patienten oplosbare 
CD54 moleculen aangetoond die de interactie van CD!la/CDIS zou kunnen 
blokkeren en daarmee ook de activatie en functie van de T -lymfocyten. 
Voor screening en detectie van getransduceerde T -lymfocyten is een hoge dichtheid van 
chimere receptoren op T -lymfocyt van belang. Expressie van chimere receptoren kan 
mede bepaald worden door bet ontwerp van de receptor. Dit kan leiden tot een 
stabielere expressie en mogelijk een verbeterde functie. Daarom is bet effect van de 
chimere receptor genstructunr op de functionele expressie bestudeerd (hoofdstuk 4). 
Hiertoe is een nieuw retroviraal gentransductie systeem ontwikkeld (STITCH). 
STITCH bestaat nit de retrovirale vector pSTITCH, de retrovirale genen gag en pol, een 
gen coderend voor bet envelop eiwit van g:tbbon ape leukemia virus, en de cellijn 293T. 
Dit systeem resulteerde in verhoogde expressie van de chimere receptor in T-
lymfocyten en een verbeterde transductie-efficientie. Daamaast is een aantal 
verschillende chimere receptor genstructuren ontworpen en is de membraanexpressie 
op T -lymfocyten bekeken. Hieruit bleek dat een kleine brugregio tussen bet 
immunoglobuline gen en bet transmembraan gen a! voldoende was voor membraan-
expressie. Dit sluit niet uit dat andere, rnisschien Iangere, brugregio's leiden tot hogere 
dichtheid van de chimere receptor op de celmembraan. 
V oor de TCR is beschreven dat de ).,waliteit en sterkte van de T -lymfocytrespons 
afhaukelijk is van de dichtheid van de TCR en bet tumorantigeen (TAA). Omdat de 
dichtheid van antigenen op tumorcellen in vivo sterk kan verschillen is er 
onderzocht hoe verschillende dichtheden van TAA op tumorcellen enerzijds en van 
chimere receptoren op T-lymfocyten anderzijds, invloed kunnen hebben op de T-
lymfocytrespons (hoofdstuk 5). Door bet gebruik van bet retrovirale transductie 
systeem STITCH zijn er T -lymfocyten beschikbaar met dezelfde chimere receptor 
maar met verschillende membraandichtheden van de chimere receptor. 
Tumorcellen met een !age dichtheid van bet TAA worden aileen vernietigd door 
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T -lymfocyten met een hoge dichtheid van de chimere receptor. Dit in tegenstelling 
tot tumorcellen met veel antigenen op de celmembraan die vemietigd worden door 
T -lymfocyten met een !age of hoge dichtheid van de chimere receptor. Om te 
voorkomen dat tumorcellen met !age antigeendichtheid ontsnappen aan de therapie 
is het gebruik van T -lymfocyten met hoge dichtheid van de chimere receptor aan te 
raden. 
Therapeutische toepassing van T-lymfocyten met chi mere receptoren 
De resultaten uit dit proefschrift en andere in vitro studies hebben aangetoond dat 
T -lymfocyten met chimere receptoren in staat zijn tumorcellen te herkennen en deze 
vervolgens te vernietigen. Om deze functie van T -lymfocyten met chimere 
receptoren in vivo te testen zijn verschillende diermodellen ontwi.kkeld. Hierin is 
aangetoond dat injectie van T -lymfocyten met chimere receptoren, specifiek voor 
een bepaalde tumorsoort) kan leiden tot remming van tumorgroei, afname van 
uitzaaiingen in de long, verlenging van de levensduur, en ophoping van de 
T-lymfocyten in naar de tumor. Deze experimenten vormen de basis voor de 
ontwikkeling van een protocol voor de behandeling van humane tumoren. Een 
mogelijk protocol dat gebruikt kan worden in de behandeling van humane tumoren 
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figuur 6.1 Immuno-gentherapie protocol voor de behandeling van nierkanker met chirnere receptor 
getransduceerde T -lymfog.ten. Perifere bloed-lymfog.ten worden afgenomen van de patient, geactiveerd 
en vervolgens getransduceerd met retrovirale vectoren die het gen voor de chimere receptor bevatten. 
Deze getransduceerde T -lymfog.ten worden verder opgekvveekt en teruggegeven aan de patient. 
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is afgebeeld in figuur 6.1. Als de tumor is getest voor de expressie van 
tumorspecifieke antigenen op de celmembraan waartegen antistoffen gemaakt zijn 
of gemaakt kunnen worden, kan de chimere receptor geconstrueerd en gekloneerd 
worden in de retrovirale vector. Perifere bloed-lymfocyten worden geisoleerd uit de 
patient, geactiveerd en getransduceerd met de retrovirale vector die het chimere 
receptor genconstruct bevat, specifiek voor niertumorcellen. Hierbij is het gebruik 
van retrovirale vectoren met hoge transductie-efficientie een voordeel omdat de 
getransduceerde T -lymfocyten dan direct terug gespoten kunnen worden zonder 
verdere selectie. Dit verkort de behandeling en behoudt de heterogeniteit van de 
T-lymfocyten populatie. Na her-infusie moeten de getransduceerde T-lymfocyten 
zich specifiek binden aan de uiertumorcellen en worden aangezet tot cytokinen 
productie en tumorcelveruietiging. 
Tenslotte 
Chimere receptoren met specificiteit voor tumor antigenen leveren een grote 
bijdrage aan het specifiek richten van T-lymfocyten tegen tumorcellen. Nu het 
technisch mogelijk is om chimere receptoren te maken, er efficiente gentransductie 
systemen zijn ontwikkeld en met experimentele dierstudies de anti-tumoreffectiviteit 
van T-lymfocyten met chimere receptoren is aangetoond, zijn de eerste klinische 
studies gestart. Hierin zullen veiligheidsaspecten van de infusie van genetisch 
gemodificeerde T -lymfocyten worden onderzocht en de aanwezigheid en lokalisatie 
van de T-lymfocyten worden bekeken. Deze eerste studies zullen bijdragen aan het 
ontwerp van optimale chimere receptoren en behandelingsprotocollen. In de 
komende jaren zal duidelijk worden of de chimere receptor benadering kan 
bijdragen aan de behandeling van kanker. 
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